AU1540599A - Human thyroid protein zsig45 and dna encoding same - Google Patents
Human thyroid protein zsig45 and dna encoding same Download PDFInfo
- Publication number
- AU1540599A AU1540599A AU15405/99A AU1540599A AU1540599A AU 1540599 A AU1540599 A AU 1540599A AU 15405/99 A AU15405/99 A AU 15405/99A AU 1540599 A AU1540599 A AU 1540599A AU 1540599 A AU1540599 A AU 1540599A
- Authority
- AU
- Australia
- Prior art keywords
- zsig45
- amino acid
- seq
- polypeptide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title description 152
- 102000004169 proteins and genes Human genes 0.000 title description 90
- 210000001685 thyroid gland Anatomy 0.000 title description 55
- 241000282414 Homo sapiens Species 0.000 title description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 370
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 349
- 229920001184 polypeptide Polymers 0.000 claims description 334
- 210000004027 cell Anatomy 0.000 claims description 241
- 238000000034 method Methods 0.000 claims description 133
- 150000001413 amino acids Chemical class 0.000 claims description 104
- 102000040430 polynucleotide Human genes 0.000 claims description 76
- 108091033319 polynucleotide Proteins 0.000 claims description 76
- 239000002157 polynucleotide Substances 0.000 claims description 76
- 230000000694 effects Effects 0.000 claims description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- 239000002773 nucleotide Substances 0.000 claims description 42
- 125000003729 nucleotide group Chemical group 0.000 claims description 42
- 125000000539 amino acid group Chemical group 0.000 claims description 36
- 239000005557 antagonist Substances 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 31
- 230000000295 complement effect Effects 0.000 claims description 28
- 230000003248 secreting effect Effects 0.000 claims description 28
- 239000000556 agonist Substances 0.000 claims description 25
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 23
- 102000037865 fusion proteins Human genes 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 22
- 239000013604 expression vector Substances 0.000 claims description 20
- 238000013518 transcription Methods 0.000 claims description 14
- 230000035897 transcription Effects 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 108700008625 Reporter Genes Proteins 0.000 claims description 6
- 238000004166 bioassay Methods 0.000 claims description 6
- 238000010256 biochemical assay Methods 0.000 claims description 4
- 230000004640 cellular pathway Effects 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000004952 protein activity Effects 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 description 98
- 235000018102 proteins Nutrition 0.000 description 87
- 235000001014 amino acid Nutrition 0.000 description 73
- 229940024606 amino acid Drugs 0.000 description 69
- 210000001519 tissue Anatomy 0.000 description 65
- 238000003556 assay Methods 0.000 description 61
- 230000014509 gene expression Effects 0.000 description 52
- 239000013598 vector Substances 0.000 description 37
- 108020004635 Complementary DNA Proteins 0.000 description 36
- 238000001727 in vivo Methods 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 102000005962 receptors Human genes 0.000 description 35
- 108020003175 receptors Proteins 0.000 description 35
- 238000010804 cDNA synthesis Methods 0.000 description 34
- 239000002299 complementary DNA Substances 0.000 description 34
- 238000011282 treatment Methods 0.000 description 30
- 201000010099 disease Diseases 0.000 description 29
- 239000012634 fragment Substances 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 27
- 241000700605 Viruses Species 0.000 description 25
- 230000027455 binding Effects 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 230000004927 fusion Effects 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 108020004705 Codon Proteins 0.000 description 21
- 230000006870 function Effects 0.000 description 21
- 239000000499 gel Substances 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 21
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000003446 ligand Substances 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 210000002216 heart Anatomy 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 241000894007 species Species 0.000 description 18
- 239000005495 thyroid hormone Substances 0.000 description 18
- 241001452677 Ogataea methanolica Species 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 229940036555 thyroid hormone Drugs 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 230000000692 anti-sense effect Effects 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 230000001817 pituitary effect Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 11
- 230000002265 prevention Effects 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- 241000701161 unidentified adenovirus Species 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000036755 cellular response Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 108010001789 Calcitonin Receptors Proteins 0.000 description 9
- 102100038520 Calcitonin receptor Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 9
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004413 cardiac myocyte Anatomy 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 241000701447 unidentified baculovirus Species 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091008324 binding proteins Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000004217 heart function Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 229960004452 methionine Drugs 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000002391 anti-complement effect Effects 0.000 description 6
- 108010008730 anticomplement Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000006539 extracellular acidification Effects 0.000 description 6
- 230000004190 glucose uptake Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 210000000963 osteoblast Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 210000005253 yeast cell Anatomy 0.000 description 6
- 206010005949 Bone cancer Diseases 0.000 description 5
- 208000018084 Bone neoplasm Diseases 0.000 description 5
- 108091029865 Exogenous DNA Proteins 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 5
- 102000004310 Ion Channels Human genes 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 208000024799 Thyroid disease Diseases 0.000 description 5
- 102000011923 Thyrotropin Human genes 0.000 description 5
- 108010061174 Thyrotropin Proteins 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000003171 anti-complementary effect Effects 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000000905 extrathyroidal effect Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000004110 gluconeogenesis Effects 0.000 description 5
- 230000004116 glycogenolysis Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 230000007257 malfunction Effects 0.000 description 5
- 210000003622 mature neutrocyte Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000035924 thermogenesis Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 101710094503 Metallothionein-1 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 108010007389 Trefoil Factors Proteins 0.000 description 4
- 102000007641 Trefoil Factors Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000011759 adipose tissue development Effects 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 210000002907 exocrine cell Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000006377 glucose transport Effects 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 210000002064 heart cell Anatomy 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 210000003917 human chromosome Anatomy 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 229960003136 leucine Drugs 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000004132 lipogenesis Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 230000007102 metabolic function Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 210000000107 myocyte Anatomy 0.000 description 4
- 230000009707 neogenesis Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 3
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 3
- 102100035882 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- -1 antibodies Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 108091005608 glycosylated proteins Proteins 0.000 description 3
- 102000035122 glycosylated proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 210000004412 neuroendocrine cell Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 102000006255 nuclear receptors Human genes 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000001322 periplasm Anatomy 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000001971 thyroidal effect Effects 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 2
- DFZVZEMNPGABKO-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-ZETCQYMHSA-N 0.000 description 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 2
- 101100437119 Arabidopsis thaliana AUG2 gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010061005 Cardiac myxoma Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010013883 Dwarfism Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 2
- 102100036509 Erythropoietin receptor Human genes 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010067193 Formaldehyde transketolase Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 2
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100020948 Growth hormone receptor Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 2
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 108091060545 Nonsense suppressor Proteins 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102100027330 Phosphoribosylaminoimidazole carboxylase Human genes 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108010068542 Somatotropin Receptors Proteins 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 241000795412 Thyriodes Species 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 102000003911 Thyrotropin Receptors Human genes 0.000 description 2
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 2
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 235000015724 Trifolium pratense Nutrition 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- ROLZYTOAMYXLMF-UHFFFAOYSA-N amino(benzyl)carbamic acid Chemical compound OC(=O)N(N)CC1=CC=CC=C1 ROLZYTOAMYXLMF-UHFFFAOYSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003491 cAMP production Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- 231100000762 chronic effect Toxicity 0.000 description 2
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000000447 dimerizing effect Effects 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 108010044853 histidine-rich proteins Proteins 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000013198 immunometric assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000006241 metabolic reaction Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 108010035774 phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000003334 potential effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 208000037905 systemic hypertension Diseases 0.000 description 2
- 230000028016 temperature homeostasis Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 230000006016 thyroid dysfunction Effects 0.000 description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UJXJZOCXEZPHIE-YFKPBYRVSA-N (2s)-2-(2-hydroxyethylamino)-4-sulfanylbutanoic acid Chemical compound OCCN[C@H](C(O)=O)CCS UJXJZOCXEZPHIE-YFKPBYRVSA-N 0.000 description 1
- KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 description 1
- JQFLYFRHDIHZFZ-RXMQYKEDSA-N (2s)-3,3-dimethylpyrrolidine-2-carboxylic acid Chemical compound CC1(C)CCN[C@@H]1C(O)=O JQFLYFRHDIHZFZ-RXMQYKEDSA-N 0.000 description 1
- CNPSFBUUYIVHAP-AKGZTFGVSA-N (2s)-3-methylpyrrolidine-2-carboxylic acid Chemical compound CC1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-AKGZTFGVSA-N 0.000 description 1
- FXGZFWDCXQRZKI-VKHMYHEASA-N (2s)-5-amino-2-nitramido-5-oxopentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)N[N+]([O-])=O FXGZFWDCXQRZKI-VKHMYHEASA-N 0.000 description 1
- CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 1
- CNPSFBUUYIVHAP-WHFBIAKZSA-N (2s,3s)-3-methylpyrrolidin-1-ium-2-carboxylate Chemical compound C[C@H]1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-WHFBIAKZSA-N 0.000 description 1
- DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- XEVFXAFXZZYFSX-UHFFFAOYSA-N 3-azabicyclo[2.1.1]hexane-4-carboxylic acid Chemical compound C1C2CC1(C(=O)O)NC2 XEVFXAFXZZYFSX-UHFFFAOYSA-N 0.000 description 1
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150096273 ADE2 gene Proteins 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 241000228431 Acremonium chrysogenum Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010048964 Carotid artery occlusion Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108700029231 Developmental Genes Proteins 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 102000011845 Iodide peroxidase Human genes 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235650 Kluyveromyces marxianus Species 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- KKJQZEWNZXRJFG-UHFFFAOYSA-N L-trans-4-Methyl-2-pyrrolidinecarboxylic acid Chemical compound CC1CNC(C(O)=O)C1 KKJQZEWNZXRJFG-UHFFFAOYSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100243377 Mus musculus Pepd gene Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 241001477931 Mythimna unipuncta Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 101150029183 PEP4 gene Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100038745 Protection of telomeres protein 1 Human genes 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 108010019653 Pwo polymerase Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 244000301083 Ustilago maydis Species 0.000 description 1
- 235000015919 Ustilago maydis Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- PCBMGUSDYHYVBQ-SOOFDHNKSA-N [4-amino-2-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazol-5-yl]phosphonic acid Chemical compound P(=O)(O)(O)C=1N=C(NC1N)C1[C@H](O)[C@H](O)[C@H](O1)CO PCBMGUSDYHYVBQ-SOOFDHNKSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000689 aminoacylating effect Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001992 atrioventricular node Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000004221 bone function Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 210000000803 cardiac myoblast Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 108091008394 cellulose binding proteins Proteins 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005831 deiodination reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000002003 electron diffraction Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 230000002039 glucoregulatory effect Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- MWFRVMDVLYIXJF-BYPYZUCNSA-N hydroxyethylcysteine Chemical compound OC(=O)[C@@H](N)CSCCO MWFRVMDVLYIXJF-BYPYZUCNSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001127 hyperphagic effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000001184 hypocalcaemic effect Effects 0.000 description 1
- 230000002806 hypometabolic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001818 nuclear effect Effects 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2220/00—Biochemical treatment
- A23C2220/20—Treatment with microorganisms
- A23C2220/202—Genetic engineering of microorganisms used in dairy technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
WO 99/28467 PCTIUS98/25454 5 Description HUMAN THYROID PROTEIN ZSIG45 AND DNA ENCODING SAME BACKGROUND OF THE INVENTION Proliferation and differentiation of cells of 10 multicellular organisms are controlled by hormones and polypeptide growth factors. These diffusable molecules allow cells to communicate with each other and act in concert to regulate cell proliferation and organ development; and regulate repair and regeneration of 15 damaged tissue. Hormones and growth factors influence cellular metabolism by binding to receptors. Receptors may be integral membrane proteins that are linked to signaling pathways within the cell. Other classes of receptors are soluble molecules, such as transcription 20 factors. Hormonal effects, including hormone and soluble receptor interaction, are essential for effective thyroid function. The thyroid gland is a major endocrine gland during normal human growth and development. In adults, 25 the major role of the thyroid is to maintain metabolic stability, primarily through thyroid hormone production and regulation. Virtually every organ in the body is affected by thyroid hormones. Thus, thyroid malfunction is associated with several disease states. Thyroid 30 diseases are relatively common, occurring in the form of thyroid gland size and shape abnormalities (goiter) and abnormalities in thyroid hormone secretion. Thyroid malfunction may also result from non-thyroidal illnesses or nutrient deficiencies that alter thyroid physiology.
WO99/28467 PCT/US98/25454 2 Examples of common thyroid diseases are thyrotoxicosis, hypothyroidism, Grave's disease, hyperthyroidism and thyroid tumors. For general review see, Felig, P, Baxter, J.D. and Frohman, L.A. (eds.), Endocrinology and 5 Metabolism, McGraw Hill, NY, 3rd ed., 1995, pp. 432-553; and Bennett, J.C. and Plum, F. (eds.), Textbook of Medicine, W.B. Saunders Co., Philadelphia, 20th ed., 1996, pp. 1227-1245. The most extensively studied thyroid hormones 10 are thyroxine (T4), triiodothyronine (T3) and thyroid stimulating hormone (TSH). T4 is produced exclusively in the thyroid, whereas T3 is produced both by the thyroid and by extra-thyroidal enzymatic 5'-deiodination of T4. Both T3 and T4 are secreted and are derived from enzymatic 15 cleavage of thyroglobulin; thyroglobulin, a major thyroid protein, is the intracellular storage form of T4 and T3. Both the biosynthesis and secretion of T4 and T3 are stimulated by pituitary TSH; which, in turn, is inhibited by circulating T3 and T4 and stimulated by hypothalamic 20 thyrotropin-releasing hormone (TRH). T3 functions as a ligand for thyroid hormone nuclear receptors, which mediate all known physiologic actions of thyroid hormone. These receptors are members of the steroid nuclear receptor superfamily; they bind DNA 25 and activate mRNA transcription. The thyroid receptor has different activities when bound or not bound by its acidic T3 ligand. In circulation, T4 and T3 are bound by several different serum proteins until they reach their sites of action in various organs and tissues. 30 Thyroid hormones modulate a wide number of metabolic processes by regulating the production and activity of various enzymes, the production and metabolism of other hormones, and utilization of substrates, vitamins, and minerals. Not all of these effects are due WO99/28467 PCTIUS98/25454 3 to T3 transcriptional regulation. For example, non nuclear actions include amino acid and sugar transport stimulation in lymphoid cells, calcium-ATPase activity in red blood cells and heart cells, and other membrane 5 interactions. For review of the metabolic effect and diseases of thyroid hormones, see Braverman, L.E. (ed.), Diseases of the Thyroid, Humana Press, Totowa, NJ, 1997. Other known effectors contribute to this complex physiologic scheme. Currently unknown effectors are 10 probably important as well. There remains a need in the art to further elucidate thyroid-related physiology and to provide additional regulatory molecules. Of particular interest are regulatory proteins, including additional thyroid 15 hormones, that influence thyroid function or are secreted from thyroid with extrathymic effects. Such hormones would be useful for, inter alia, restoring normal thyroid function in patients suffering various thyroid ailments and as targets for the development of small-molecule 20 drugs. The demonstrated in vivo activities of known thyroid hormones illustrates the enormous clinical potential of, and need for, other thyroid hormones, their agonists and antagonists. The present invention provides such polypeptides for these and other uses that should be 25 apparent to those skilled in the art from the teachings herein. SUMMARY OF THE INVENTION In one aspect, the present invention provides, 30 an isolated polynucleotide that encodes a polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of: (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to WO 99/28467 PCT/US98/25454 4 amino acid number 114 (Asp) of SEQ ID NO:2; (b) the amino acid sequence as shown in SEQ ID NO:4 from amino acid number 1 (Met) to amino acid number 85 (Asp); (c) the amino acid sequence as shown in SEQ ID NO:3 from amino 5 acid number 1 (Met) to amino acid number 89 (Asp); (d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid residue number 1 (Met) to amino acid residue number 114 (Asp). In one embodiment, the present invention provides an isolated polynucleotide molecule selected from 10 the group consisting of: (a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:l from nucleotide 219 to nucleotide 422; (b) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:l from nucleotide 168 to nucleotide 422; (c) 15 polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:l from nucleotide 156 to nucleotide 422; (d) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:1 from nucleotide 82 to nucleotide 422; and (e) polynucleotide molecules 20 complementary to (a), (b), (c), or (d). In another embodiment, the polynucleotide disclosed above comprises nucleotide 1 to nucleotide 342 of SEQ ID NO:15. In another embodiment, the polynucleotide disclosed above consists of a sequence of amino acid residues that is at 25 least 90% identical the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2. In another embodiment, the polynucleotide disclosed above consists of a sequence of amino acid residues that is as shown in SEQ ID NO:2 30 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2. In another embodiment, the polynucleotide disclosed above encodes a polypeptide, wherein the polypeptide contains motifs 1 through 5.
WO99/28467 PCTIUS98/25454 5 In a second aspect, the present invention provides an expression vector comprising the following operably linked elements: a transcription promoter; a DNA segment encoding a zsig45 polypeptide that is 90% 5 identical to and amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2; and a transcription terminator. In one embodiment, the expression vector disclosed above further comprises a secretory signal sequence operably 10 linked to the DNA segment. In another embodiment, the expression vector disclosed above comprises a secretory signal sequence selected from the group consisting of: (a) amino acids 1 through 46 of SEQ ID NO:2; (b) amino acids 1 through 21 of SEQ ID NO:3; and (c) amino acids 1 15 through 17 of SEQ ID NO:4. In a third aspect, the present invention provides a cultured cell into which has been introduced an expression vector as disclosed above, wherein the cell expresses a polypeptide encoded by the DNA segment. 20 In a fourth aspect, the present invention provides a DNA construct encoding a fusion protein, the DNA construct comprising: a first DNA segment encoding a polypeptide that is at least 90% identical to a sequence of amino acids selected from the group consisting of: (a) 25 amino acids 1 through 46 of SEQ ID NO:2; (b) amino acids 1 through 21 of SEQ ID NO:3; and (c) amino acids 1 through 17 of SEQ ID NO:4;and a second DNA segment encoding an additional polypeptide, wherein the first and second DNA segments are connected in-frame; and encode the fusion 30 protein. In another aspect, the present invention provides an isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of: WO 99/28467 PCTIUS98/25454 6 (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2; (b) the amino acid sequence as shown in SEQ ID NO:4 from amino acid number 1 (Met) to amino acid 5 number 85 (Asp); (c) the amino acid sequence as shown in SEQ ID NO:3 from amino acid number 1 (Met) to amino acid number 89 (Asp); (d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid residue number 1 (Met) to amino acid residue number 114 (Asp) In one embodiment, 10 the isolated polypeptide disclosed above consists of a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp). In another embodiment, the isolated polypeptide 15 disclosed above is as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp). In another embodiment, the isolated polypeptide disclosed above contains motifs 1 through 5. In another aspect, the present invention 20 provides, a method of producing a zsig45 polypeptide comprising: culturing a cell into which has been introduced an expression vector as disclosed above; and isolating the zsig45 polypeptide produced by the cell. In another aspect, the present invention 25 provides, a method of producing an antibody to zsig45 polypeptide comprising: inoculating an animal with a polypeptide selected from the group consisting of: (a) a polypeptide consisting of 9 to 67 amino acids, wherein the polypeptide is at least 90% identical to a contiguous 30 sequence of amino acids in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp); and (b) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp); and wherein the polypeptide elicits an WO99/28467 PCT/US98/25454 7 immune response in the animal to produce the antibody; and isolating the antibody from the animal. In another aspect, the present invention provides, an antibody produced by the method disclosed 5 above, which binds to a zsig45 polypeptide. In one embodiment, the antibody disclosed above is a monoclonal antibody. In another aspect, the present invention provides, an antibody which binds to a polypeptide disclosed above. 10 In another aspect, the present invention provides, a method of detecting, in a test sample, the presence of an antagonist of zsig45 protein activity, comprising: transfecting a zsig45-responsive cell, with a reporter gene construct that is responsive to a zsig45 15 stimulated cellular pathway; and producing a zsig45 polypeptide by the method disclosed above; and adding the zsig45 polypeptide to the cell, in the presence and absence of a test sample; and comparing levels of response to the zsig45 polypeptide, in the presence and absence of 20 the test sample, by a biological or biochemical assay; and determining from the comparison, the presence of the antagonist of zsig45 activity in the test sample. In another aspect, the present invention provides, a method of detecting, in a test sample, the 25 presence of an agonist of zsig45 protein activity, comprising: transfecting a zsig45-responsive cell, with a reporter gene construct that is responsive to a zsig45 stimulated cellular pathway; and adding a test sample; and comparing levels of response in the presence and absence 30 of the test sample, by a biological or biochemical assay; and determining from the comparison, the presence of the agonist of zsig45 activity in the test sample.
WO 99/28467 PCT/US98/25454 8 These and other aspects of the invention will become evident upon reference to the following detailed description of the invention.. 5 DETAILED DESCRIPTION OF THE INVENTION Prior to setting forth the invention in detail, it is helpful to the understanding thereof to define the following terms: The term "affinity tag" is used herein to denote 10 a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific 15 binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67:31, 1988), Glu-Glu affinity 20 tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. USA 82:7952-4, 1985), substance P, Flag T M peptide (Hopp et al., Biotechnology 6:1204-10, 1988), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., Protein Expression and 25 Purification 2: 95-107, 1991. DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ). The term "allelic variant" is used herein to denote any of two or more alternative forms of a gene 30 occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in genotypic and phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered WO 99/28467 PCT/US98/25454 9 amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene. The terms "amino-terminal" and "carboxyl 5 terminal" are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl 10 terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide. The term "complement/anti-complement pair" 15 denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include 20 receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding 25 affinity of <10 9 M-1. The term "complements of a polynucleotide molecule" is a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the 30 sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'. The term "contig" denotes a polynucleotide that has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences WO99/28467 PCT/US98/25454 10 are said to "overlap" a given stretch of polynucleotide sequence either in their entirety or along a partial stretch of the polynucleotide. For example, representative contigs to the polynucleotide sequence 5' 5 ATGGCTTAGCTT-3' are 5'-TAGCTTgagtct-3' and 3' gtcgacTACCGA-5'. The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference 10 polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp). The term "expression vector" is used to denote a 15 DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of 20 replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both. The term "isolated", when applied to a 25 polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are 30 those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as WO99/28467 PCT/US98/25454 11 promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985). 5 An "isolated" polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, 10 particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e., greater than 95% pure, more preferably greater than 99% pure. When used in this context, the term "isolated" does not exclude the presence of the same 15 polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms. The term "operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, 20 e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator. The term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different 25 species. Sequence differences among orthologs are the result of speciation. "Paralogs" are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, a-globin, p 30 globin, and myoglobin are paralogs of each other. A "polynucleotide" is a single- or double stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural WO99/28467 PCTIUS98/25454 12 sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the 5 context allows, the latter two terms may describe polynucleotides that are single-stranded or double stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term "base pairs". It 10 will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide 15 molecule may not be paired. A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as 20 "peptides". The term "promoter" is used herein for its art recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter 25 sequences are commonly, but not always, found in the 5' non-coding regions of genes. A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non peptidic components, such as carbohydrate groups. 30 Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone WO99/28467 PCTIUS98/25454 13 structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless. The term "receptor" denotes a cell-associated protein that binds to a bioactive molecule (i.e., a 5 ligand) and mediates the effect of the ligand on the cell. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor,
GM
10 CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor). Membrane-bound receptors are characterized by a multi-peptide structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal 15 transduction. Most nuclear receptors also exhibit a multi domain structure, including an amino-terminal, transactivating domain, a DNA binding domain, and a ligand binding domain. Binding of ligand to receptor results in a conformational change in the receptor that causes an 20 interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, 25 dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., 30 thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).
WO99/28467 PCTIUS98/25454 14 The term "secretory signal sequence" denotes a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway 5 of a cell in which it is synthesized. The larger peptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway. The term "splice variant" is used herein to denote alternative forms of RNA transcribed from a gene. 10 Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene. Splice variants may encode 15 polypeptides having altered amino acid sequences. The term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene. Molecular weights and lengths of polymers 20 determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to ±10%. 25 Teachings of all references cited herein are in their entirety incorporated by reference. The present invention is based in part upon the discovery of a novel DNA sequence that encodes a 30 polypeptide having a secretory signal sequence. Analysis of the tissue distribution of the mRNA corresponding to this novel cDNA showed that expression was restricted mainly to the thyroid. Expression was also evident in the pituitary and colon. This tissue-specific expression WO99/28467 PCT/US98/25454 15 indicates a role in thyroid function. The polypeptide has been designated zsig45.The novel zsig45 polypeptides of the present invention were initially identified by querying an EST database for secretory signal sequences in 5 an effort to select for secreted proteins. These sequences are characterized by an upstream methionine start site, a hydrophobic region of approximately 13 amino acids, and a cleavage site. Polypeptides corresponding to ESTs meeting these search criteria were compared to known 10 sequences to identify secreted proteins having homology to known ligands. A single EST sequence was isolated and predicted to be a secreted protein. The novel polypeptide encoded by the full length cDNA has no apparent homolog relationship to known proteins, suggesting a completely 15 novel protein that may be a member of a new protein family. Moreover, the signal sequence, predicted small size (8 kD, without post-translational modification), tissue-specific expression, certain novel motifs disclosed herein, and lack of long hydrophobic segments in the 20 mature protein, suggests a small secreted molecule with potential as a new class of secreted cytokine-like or protein hormone-like molecules. The nucleotide sequence of a representative zsig45-encoding DNA is described in SEQ ID NO. 1, and its 25 deduced amino acid sequence is described in SEQ ID NO. 2. Analysis of the DNA encoding a zsig45 polypeptide (SEQ ID NO:1) revealed an open reading frame encoding 114 amino acids (SEQ ID NO:2) comprising a signal peptide of 46 amino acid residues (residue 1 (Met), to residue 46 (Ala) 30 of SEQ ID NO:2) and a mature polypeptide of 68 amino acids (residue 47 (Lys) to residue 114 (Asp) of SEQ ID NO:2). Analysis of the DNA encoding a zsig45 polypeptide (SEQ ID NO:1) also revealed three potential Methionine start residues that would enable translation WO99/28467 PCT/US98/25454 16 initiation. The first is amino acid residue 1, the second is amino acid residue 26, and the third is amino acid residue 30 (See, SEQ ID NO:2). Thus, in addition to the first open reading frame disclosed above, there are two 5 other open reading frames (ORFs) encoded by the same polynucleotide. These ORFs would encode the same mature polypeptide disclosed above. Analysis of the DNA encoding the zsig45 polypeptide (SEQ ID NO:2) revealed a second open reading frame encoding 89 amino acids (SEQ ID NO:3) 10 containing a signal peptide of 21 amino acid residues (residue 1 (Met), to residue 21 (Ala) of SEQ ID NO:3), and a third open reading frame encoding 85 amino acids (SEQ ID NO:4) containing a signal peptide of 17 amino acid residues (residue 1 (Met), to residue 17 (Ala) of SEQ ID 15 NO:4). In proteins, regions of low variance (e.g., hydrophobic clusters) are often conserved in regions of structural importance (Sheppard, P., et al., Gene 150:163 167, 1994). Such regions of low variance often contain 20 rare or infrequent amino acids, such as Tryptophan. Examining the low variance regions of zsig45 revealed the following five small regions of predicted conserved amino acids, referred to hereinafter as motifs 1 through 5: motif 1 (SEQ ID NO:5; corresponding to amino acids 50 to 25 56 of SEQ ID NO:2); motif 2 (SEQ ID NO:6; corresponding to amino acids 61 to 66 of SEQ ID NO:2); motif 3 (SEQ ID NO:7; corresponding to amino acids 71 to 76 of SEQ ID NO:2); motif 4 (SEQ ID NO:8; corresponding to amino acids 87 to 92 of SEQ ID NO:2); and motif 5 (SEQ ID NO:9; 30 corresponding to amino acids 95 to 100 of SEQ ID NO:2). The presence of conserved or low variance motifs generally correlates with or defines important structural regions in proteins. The regions between such motifs may be more variable, but are often functionally significant WO99/28467 PCT/US98/25454 17 because they may relate to or define important structures and activities such as binding domains, biological and enzymatic activity, signal transduction, cell-cell interaction, tissue localization domains and the like. 5 The highly conserved amino acids in motifs 1 through 5 of zsig45 can be used as a tool to identify new family members. For instance, reverse transcription polymerase chain reaction (RT-PCR) can be used to amplify 10 sequences encoding the conserved motifs from RNA obtained from a variety of tissue sources or cell lines. In particular, highly degenerate oligonucleotide primers designed from the following zsig45 amino acid sequences of motifs 1 through 5 are useful for this purpose: 15 a) QEEGDP (motif 1; SEQ ID NO:5), corresponding to degenerate polynucleotides of SEQ ID NO:10 and their complement; b) AMPYWP (motif 2; SEQ ID NO:6), corresponding to degenerate polynucleotides of SEQ ID NO:11 and their 20 complement; c) DFWNYV (motif 3; SEQ ID NO:7), corresponding to degenerate polynucleotides of SEQ ID NO:12 and their complement; d) QIEDMA (motif 4; SEQ ID NO:8), corresponding 25 to degenerate polynucleotides of SEQ ID NO:13 and their complement; and e) FFAHFP (motif 5; SEQ ID NO:9), corresponding to degenerate polynucleotides of SEQ ID NO:14 and their complement. 30 The corresponding polynucleotides encoding the zsig45 polypeptide regions, domains, motifs, residues and sequences described above are as shown in SEQ ID NO:1. SEQ ID NO:15 is a degenerate polynucleotide sequence that encompasses all polynucleotides that encode WO99/28467 PCT/US98/25454 18 the zsig45 polypeptide of SEQ ID NO:2 (amino acids 1-114). Thus, zsig45 polypeptide-encoding polynucleotides ranging from nucleotide 1 or 141 to nucleotide 342 of SEQ ID NO:15 are contemplated by the present invention. Also 5 contemplated by the present invention are fragments and fusions as described herein with respect to SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, which are formed from analogous regions of SEQ ID NO:15. The symbols in SEQ ID NO:15 are summarized in Table 1 below. 10 WO 99/28467 PCT/US98/25454 19 TABLE 1 Nucleotide Resolution Complement Resolution A A T T C C G G G G C C T T A A R AIG Y CIT Y CIT R AIG M AIC K GIT K GIT M AIC S CIG S CIG W AIT W AIT H AICIT D AIGIT B C GIT V AICIG V AIClG B CIGIT D AIGIT H AICIT N AIClGIT N AICIGIT The degenerate codons used in SEQ ID NO:15, 5 encompassing all possible codons for a given amino acid, are set forth in Table 2 below.
WO99/28467 PCT/US98/25454 20 TABLE 2 Amino Letter Codons Degenerate Acid Codon Cys C TGC TGT TGY Ser S AGC AGT TCA TCC TCG TCT WSN Thr T ACA ACC ACG ACT ACN Pro P CCA CCC CCG CCT CCN Ala A GCA GCC GCG GCT GCN Gly G GGA GGC GGG GGT GGN Asn N AAC AAT AAY Asp D GAC GAT GAY Glu E GAA GAG GAR Gln Q CAA CAG CAR His H CAC CAT CAY Arg R AGA AGG CGA CGC CGG CGT MGN Lys K AAA AAG AAR Met M ATG ATG Ile I ATA ATC ATT ATH Leu L CTA CTC CTG CTT TTA TTG YTN Val V GTA GTC GTG GTT GTN Phe F TTC TTT TTY Tyr Y TAC TAT TAY Trp W TGG TGG Ter TAA TAG TGA TRR AsnlAsp B RAY GlulGln Z SAR Any X NNN Gap One of ordinary skill in the art will appreciate 5 that some ambiguity is introduced in determining a degenerate codon, representative of all possible codons encoding each amino acid. For example, the degenerate WO99/28467 PCT/US98/25454 21 codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding 5 phenylalanine and leucine. Thus, some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3 or SEQ 10 ID NO:4. Such variant sequences can be tested for functionality as disclosed herein. One of ordinary skill in the art will also appreciate that different species can exhibit "preferential codon usage." In general, see, Grantham, et 15 al., Nuc. Acids Res., 8:1893-1912, 1980; Haas, et al. Curr. Biol., 6:315-324, 1996; Wain-Hobson, et al., Gene, 13:355-364, 1981; Grosjean, H., and Fiers, W., Gene, 18:199-209, 1982; Holm, L., Nuc. Acids Res., 14:3075-3087, 1986; and Ikemura, T., J. Mol. Biol., 158:573-597, 1982. 20 As used herein, the terms "preferential codon usage" and "preferential codons" are terms of art referring to protein translation codons that are most frequently used in cells of a certain species, thus favoring one or a few representatives of the possible codons encoding each amino 25 acid (See Table 2). For example, the amino acid Threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian cells ACC is the most commonly used codon; in other species, for example, insect cells, yeast, viruses or bacteria, different Thr codons may be preferential. 30 Preferential codons for a particular species can be introduced into the polynucleotides of the present invention by a variety of methods known in the art. Introduction of preferential codon sequences into recombinant DNA can, for example, enhance production of WO99/28467 PCT/US98/25454 22 the protein by making protein translation more efficient within a particular cell type or species. Therefore, the degenerate codon sequence disclosed in SEQ ID NO:15 serves as a template for optimizing expression of polynucleotides 5 in various cell types and species commonly used in the art and disclosed herein. Sequences containing preferential codons can be tested and optimized for expression in various species, and tested for functionality as disclosed herein. 10 Within preferred embodiments of the invention the isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO:l, or a sequence complementary thereto, under stringent conditions. In general, 15 stringent conditions are selected to be about 5 0 C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly 20 matched probe. Suitable stringent hybridization conditions are equivalent to about a 5 h to overnight incubation at about 42 0 C in a solution comprising: about 40-50% formamide, up to about 5X SSC, about 5X Denhardt's solution, up to about 10% dextran sulfate, and about 10-20 25 g/ml denatured commercially-available carrier DNA; hybridization is then followed by washing filters in up to about 2X SSC. For example, a suitable wash stringency is equivalent to 0.1X SSC to 2X SSC, 0.1% SDS, at 550C to 650C. Stringent hybridization and wash conditions depend 30 on the length of the probe, reflected in the Tm, hybridization and wash solutions used, and are routinely determined empirically by one of skill in the art.
WO99/28467 PCT/US98/25454 23 As previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for preparing DNA and RNA are well known in the art. In general, RNA is isolated from a tissue or 5 cell that produces large amounts of zsig45 RNA. Such tissues and cells are identified by Northern blotting (Thomas, Proc. Natl. Acad. Sci. USA 77:5201, 1980), and include thyroid, although DNA can also be prepared using RNA from other tissues or cell lines or isolated as 10 genomic DNA. Total RNA can be prepared using guanidinium isothiocyanate extraction followed by isolation by centrifugation in a CsCl gradient (Chirgwin et al., Biochemistry 18:52-94, 1979). Poly (A) + RNA is prepared from total RNA using the method of Aviv and Leder (Proc. 15 Natl. Acad. Sci. USA 69:1408-1412, 1972). Complementary DNA (cDNA) is prepared from poly(A) + RNA using known methods. In the alternative, genomic DNA can be isolated. Polynucleotides encoding zsig45 polypeptides are then identified and isolated by, for example, hybridization or 20 PCR. A full-length clone encoding zsig45 can be obtained by conventional cloning procedures. Complementary DNA (cDNA) clones are preferred, although for some applications (e.g., expression in transgenic 25 animals) it may be preferable to use a genomic clone, or to modify a cDNA clone to include at least one genomic intron. Methods for preparing cDNA and genomic clones are well known and within the level of ordinary skill in the art, and include the use of the sequence disclosed herein, 30 or parts thereof, for probing or priming a library. Expression libraries can be probed with antibodies to zsig45, receptor fragments, or other specific binding partners.
WO99/28467 PCT/US98/25454 24 The polynucleotides of the present invention can also be synthesized using DNA synthesis machines. Currently the method of choice is the phosphoramidite method. If chemically synthesized double stranded DNA is 5 required for an application such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately. The production of short polynucleotides (60 to 80 bp) is technically straightforward and can be accomplished by synthesizing the complementary strands and 10 then annealing them. However, for producing longer polynucleotides (>300 bp), special strategies are usually employed, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%. To overcome this problem, synthetic genes (double-stranded) are 15 assembled in modular form from single-stranded fragments that are from 20 to 100 nucleotides in length. One method for building a synthetic gene requires the initial production of a set of overlapping, complementary oligonucleotides, each of which is between 20 20 to 60 nucleotides long. Each internal section of the gene has complementary 3' and 5' terminal extensions designed to base pair precisely with an adjacent section. Thus, after the gene is assembled, process is completed by sealing the nicks along the backbones of the two strands 25 with T4 DNA ligase. In addition to the protein coding sequence, synthetic genes can be designed with terminal sequences that facilitate insertion into a restriction endonuclease site of a cloning vector. An alternative way to prepare a full-length gene 30 is to synthesize a specified set of overlapping oligonucleotides (40 to 100 nucleotides). After the 3' and 5' short overlapping complementary regions are annealed, large gaps still remain, but the short base-paired regions are both long enough and stable enough to hold the WO99/28467 PCT/US98/25454 25 structure together. The gaps are filled and the DNA duplex is completed via enzymatic DNA synthesis by E. coli DNA polymerase I. After the enzymatic synthesis is completed, the nicks are sealed. Double-stranded constructs are 5 sequentially linked to one another to form the entire gene sequence which is verified by DNA sequence analysis. See Glick and Pasternak, Molecular Biotechnology, Principles & Applications of Recombinant DNA, (ASM Press, Washington, D.C. 1994); Itakura et al., Annu. Rev. Biochem. 53: 323 10 56, 1984 and Climie et al., Proc. Natl. Acad. Sci. USA 87:633-7, 1990. The present invention further provides counterpart polypeptides and polynucleotides from humans (paralogs) and from other species (orthologs). These 15 species include, but are not limited to, mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and invertebrate species. Of particular interest are zsig45 human paralogs and polypeptides from other mammalian species, including murine, rat, porcine, ovine, bovine, 20 canine, feline, equine and other primate proteins. Species homologs of the human polypeptides. Orthologs of human zsig45 can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For 25 example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses zsig45 as disclosed herein. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared 30 from mRNA of a positive tissue or cell line. A zsig45 encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be WO99/28467 PCT/US98/25454 26 cloned using the polymerase chain reaction, or PCR (Mullis, U.S. Patent No. 4,683,202), using primers designed from the representative human zsig45 sequence disclosed herein. Within an additional method, the cDNA 5 library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to zsig45 polypeptide. Similar techniques can also be applied to the isolation of genomic clones. 10 Those skilled in the art will recognize that the sequence disclosed in SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4 represent a single allele of the human zsig45 gene and polypeptide, and that allelic variation and alternative splicing are expected to occur. 15 Allelic variants of this sequence can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Allelic variants of the DNA sequence shown in SEQ ID NO:1, including those containing silent mutations and those in which mutations 20 result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of SEQ ID NO:3 and SEQ ID NO:4. cDNAs generated from alternatively spliced mRNAs, which retain the properties of the zsig45 25 polypeptide are included within the scope of the present invention, as are polypeptides encoded by such cDNAs and mRNAs. Allelic variants and splice variants of these sequences can be cloned by probing cDNA or genomic libraries e.g. a human thyroid cDNA library, from 30 different individuals or tissues according to standard procedures known in the art. The present invention also provides isolated zsig45 polypeptides that are substantially homologous to the polypeptides of SEQ ID NO:2, SEQ ID NO:3 and SEQ ID WO99/28467 PCT/US98/25454 27 NO:4 and their human paralogs or species orthologs. The term "substantially similar" is used herein to denote polypeptides having 50%, preferably 60%, more preferably at least 80%, sequence identity to the sequences shown in 5 SEQ ID NO:2 or their paralogs or orthologs. Such polypeptides will more preferably be at least 90% identical, and most preferably 95% or more identical to SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4 or its paralogs or orthologs. Percent sequence identity is determined by 10 conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-616, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a 15 gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and Henikoff (ibid.) as shown in Table 3 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as: Total number of identical matches 20 x 100 [length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences] WO 99/28467 PCT/US98/25454 28 I I I- I I I I i L- ( N -D l) H r N (N I I I I II I < NNom4 H m H Ln ( (N H H H H H I I I I m H rm H c H m (Na m N (N N 0 H o( H N H H II I I I OZI N M H D m (N r m H m I I I I mmm H Ha( H ((N Nm I I I I I N co0 ~m N D CN N m m I I I I I II I Q (N M H N M H CD Hm N( I I I I I I I I (N D q N H Mm H D H NH (N I I I I I i I U m Hmm H mom H Hm HG (N HoHmNmo I I I I I I I I II I I I1I I I I I I I I I II II Z 1. H 0 0 0 0 H (N mH ( III I I I m.0 D m H D (ND m N N H m N H H F: N N H D ( H H 4 H H 4 (N H H -D R m (N I III I mnC inC WO99/28467 PCT/US98/25454 29 Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above. Variant zsig45 polypeptides or substantially 5 homologous zsig45 polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 4) and other substitutions that do not significantly 10 affect the folding or activity of the polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that 15 facilitates purification (an affinity tag), such as a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67:31, 1988), maltose binding protein (Kellerman and 20 Ferenci, Methods Enzymol. 90:459-463, 1982; Guan et al., Gene 67:21-30, 1987), thioredoxin, ubiquitin, cellulose binding protein, T7 polymerase, or other antigenic epitope or binding domain. See, in general Ford et al., Protein Expression and Purification 2: 95-107, 1991. DNAs 25 encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ; New England Biolabs, Beverly, MA). The present invention thus includes polypeptides of from about 60 to about 150 amino acid residues that comprise a sequence that is at least 30 80%, preferably at least 90%, and more preferably 95% or more identical to the corresponding region of SEQ ID NO:2. Polypeptides comprising affinity tags can further comprise a proteolytic cleavage site between the zsig45 polypeptide WO99/28467 PCT/US98/25454 30 and the affinity tag. Preferred such sites include thrombin cleavage sites and factor Xa cleavage sites. Table 4 5 Conservative amino acid substitutions Basic: arginine lysine 10 histidine Acidic: glutamic acid aspartic acid Polar: glutamine asparagine 15 Hydrophobic: leucine isoleucine valine Aromatic: phenylalanine tryptophan 20 tyrosine Small: glycine alanine serine threonine 25 methionine The proteins of the present invention can also comprise non-naturally occurring amino acid residues. Non-naturally occurring amino acids include, without 30 limitation, trans-3-methylproline, 2,4-methanoproline, cis-4-hydroxyproline, trans-4-hydroxyproline,
N
methylglycine, allo-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, WO99/28467 PCT/US98/25454 31 thiazolidine carboxylic acid, dehydroproline, 3- and 4 methylproline, 3,3-dimethylproline, tert-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4 azaphenylalanine, and 4-fluorophenylalanine. Several 5 methods are known in the art for incorporating non naturally occurring amino acid residues into proteins. For example, an in vitro system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing 10 amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is carried out in a cell-free system comprising an E. coli S30 extract and commercially available enzymes and other reagents. Proteins are 15 purified by chromatography. See, for example, Robertson et al., J. Am. Chem. Soc. 113:2722, 1991; Ellman et al., Methods Enzymol. 202:301, 1991; Chung et al., Science 259:806-809, 1993; and Chung et al., Proc. Natl. Acad. Sci. USA 90:10145-10149, 1993). In a second method, 20 translation is carried out in Xenopus oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., J. Biol. Chem. 271:19991-19998, 1996). Within a third method, E. coli cells are cultured in the absence of a natural amino 25 acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4 azaphenylalanine, or 4-fluorophenylalanine). The non naturally occurring amino acid is incorporated into the 30 protein in place of its natural counterpart. See, Koide et al., Biochem. 33:7470-7476, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by in vitro chemical modification. Chemical modification can be combined with site-directed WO99/28467 PCTIUS98/25454 32 mutagenesis to further expand the range of substitutions (Wynn and Richards, Protein Sci. 2:395-403, 1993). A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic 5 code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for zsig45 amino acid residues. Essential amino acids in the zsig45 polypeptides of the present invention can be identified according to 10 procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244: 1081-1085, 1989; Bass et al., Proc. Natl. Acad. Sci. USA 88:4498-502, 1991). In the latter technique, single alanine mutations are introduced 15 at every residue in the molecule, and the resultant mutant molecules are tested for biological or biochemical activity (e.g., in situ localization or expression of zsig45; secretion followed by detection by antibodies; or activity measured by a signal transduction type assay) as 20 disclosed below to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et al., J. Biol. Chem. 271:4699-4708, 1996. Sites of ligand- receptor or other biological interaction can also be determined by physical analysis of structure, as 25 determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., Science 255:306-312, 1992; Smith et al., J. 30 Mol. Biol. 224:899-904, 1992; Wlodaver et al., FEBS Lett. 309:59-64, 1992. The identities of essential amino acids can also be inferred from analysis of homologies with related family members.
WO99/28467 PCT/US98/25454 33 Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241:53-57, 1988) or Bowie and Sauer (Proc. 5 Natl. Acad. Sci. USA 86:2152-2156, 1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of 10 allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., Biochem. 30:10832-10837, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis (Derbyshire et al., Gene 15 46:145, 1986; Ner et al., DNA 7:127, 1988). Variants of the disclosed zsig45 DNA and polypeptide sequences can be generated through DNA shuffling as disclosed by Stemmer, Nature 370:389-91, 1994, Stemmer, Proc. Natl. Acad. Sci. USA 91:10747-51, 20 1994 and WIPO Publication WO 97/20078. Briefly, variant DNAs are generated by in vitro homologous recombination by random fragmentation of a parent DNA followed by reassembly using PCR, resulting in randomly introduced point mutations. This technique can be modified by using 25 a family of parent DNAs, such as allelic variants or DNAs from different species, to introduce additional variability into the process. Selection or screening for the desired activity, followed by additional iterations of mutagenesis and assay provides for rapid "evolution" of 30 sequences by selecting for desirable mutations while simultaneously selecting against detrimental changes. Mutagenesis methods as disclosed herein can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides in WO99/28467 PCT/US98/25454 34 host cells. Mutagenized DNA molecules that encode active polypeptides (e.g., secreted and detected by antibodies; or measured by a signal transduction type assay) can be recovered from the host cells and rapidly sequenced using 5 modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure. Using the methods discussed herein, one of 10 ordinary skill in the art can identify and/or prepare a variety of polypeptides that are substantially homologous to SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or allelic variants thereof and retain the functional and structural properties of the wild-type protein. For example, using 15 the methods described above, one could identify a receptor binding domain on zsig45; an extracellular ligand-binding domain of a receptor for zsig45;heterodimeric and homodimeric binding domains; other functional or structural domains; affinity tags; or other domains 20 important for protein-protein interactions or signal transduction. Such polypeptides may also include additional polypeptide segments, such as affinity tags, as generally disclosed above. The present invention further provides a variety 25 of other polypeptide fusions and related multimeric proteins comprising one or more polypeptide fusions. For example, a zsig45 polypeptide can be prepared as a fusion to a dimerizing protein as disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584. Preferred dimerizing proteins in 30 this regard include immunoglobulin constant region domains. Immunoglobulin zsig45 polypeptide fusions can be expressed in genetically engineered cells to produce a variety of multimeric zsig45 analogs. Auxiliary domains can be fused to zsig45 polypeptides to target them to WO99/28467 PCT/US98/25454 35 specific cells, tissues, or macromolecules (e.g., collagen). For example, a zsig45 polypeptide or protein could be targeted to a predetermined cell type by fusing a zsig45 polypeptide to a ligand that specifically binds to 5 a receptor on the surface of the target cell. In this way, polypeptides and proteins can be targeted for therapeutic or diagnostic purposes. A zsig45 polypeptide can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain. Polypeptide 10 fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al., Connective Tissue Research 34:1-9, 1996. For any zsig45 polypeptide, including variants and fusion proteins, one of ordinary skill in the art can 15 readily generate a fully degenerate polynucleotide sequence encoding that variant using the information set forth in Tables 1 and 2 above. The zsig45 polypeptides of the present 20 invention, including full-length polypeptides, biologically active fragments, and fusion polypeptides, can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or 25 transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and 30 introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, and Ausubel et al., WO99/28467 PCT/US98/25454 36 eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987. In general, a DNA sequence encoding a zsig45 polypeptide of the present invention is operably linked to 5 other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled 10 in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and 15 other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers. To direct a zsig45 polypeptide into the 20 secretory pathway of a host cell, a secretory signal sequence (also known as a secretory peptide, leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of the zsig45 polypeptide, or may be derived from 25 another secreted protein (e.g., t-PA) or synthesized de novo. The secretory signal sequence is operably linked to the zsig45 DNA sequence, i.e., the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized polypeptide into the 30 secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of interest, although certain secretory signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., WO99/28467 PCT/US98/25454 37 U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830). Alternatively, the secretory signal sequence contained in the polypeptides of the present invention is 5 used to direct other polypeptides into the secretory pathway. The present invention provides for such signal fusion polypeptides. A DNA construct encoding a signal fusion polypeptide can be made wherein a signal sequence encoding a secretory peptide derived from any one of the 10 three ORFs disclosed in SEQ ID NO:2 (amino acids 1 through 46 of SEQ ID NO:2), SEQ ID NO:3 (amino acids 1 through 21 of SEQ ID NO:3), or SEQ ID NO:4 (amino acids 1 through 17 of SEQ ID NO:4) and is operably linked to an another polypeptide using methods known in the art and disclosed 15 herein. The secretory signal sequence contained in the fusion polypeptides of the present invention is preferably fused amino-terminally to an additional peptide to direct the additional peptide into the secretory pathway. Such constructs have numerous applications known in the art. 20 For example, these novel secretory signal sequence fusion constructs can direct the secretion of an active component of a normally non-secreted protein. Such fusions may be used in vivo or in vitro to direct peptides through the secretory pathway. 25 Cultured mammalian cells are suitable hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 30 7:603, 1981: Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et al., ibid.), and liposome-mediated transfection (Hawley-Nelson et al., Focus 15:73, 1993; Ciccarone et al., Focus 15:80, WO99/28467 PCT/US98/25454 38 1993), and viral vectors (A. Miller and G. Rosman, BioTechniques 7:980-90, 1989; Q. Wang and M. Finer, Nature Med. 2:714-16, 1996). The production of recombinant polypeptides in cultured mammalian cells is disclosed, for 5 example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134. Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK 10 (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol. 36:59 72, 1977) and Chinese hamster ovary (e.g. CHO-KI; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories 15 such as the American Type Culture Collection, Manassas, VA. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from 20 metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter. Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been 25 inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is 30 a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin type drug, such as G-418 or the like. Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as WO 99/28467 PCTIUS98/25454 39 "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high 5 levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g., hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can 10 also be used. Alternative markers that introduce an altered phenotype, such as green fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase may be used to sort transfected cells from untransfected cells by such means 15 as FACS sorting or magnetic bead separation technology. Other higher eukaryotic cells can also be used as hosts, including plant cells, insect cells and avian cells. The use of Agrobacterium rhizogenes as a vector for expressing genes in plant cells has been reviewed by 20 Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987 and WIPO publication WO 94/06463. Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al., U.S. Patent No. 4,775,624; and WIPO 25 publication WO 94/06463. The use of Agrobacterium rhizogenes as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987. Fungal cells, including yeast cells, and 30 particularly cells of the genus Saccharomyces, can also be used within the present invention, such as for producing zsig45 polypeptides, zsig45 polypeptide fragments or polypeptide fusions. Methods for Insect cells can be infected with recombinant baculovirus, commonly derived WO99/28467 PCT/US98/25454 40 from Autographa californica nuclear polyhedrosis virus (AcNPV). See, King, L.A. and Possee, R.D., The Baculovirus Expression System: A Laboratory Guide, London, Chapman & Hall; O'Reilly, D.R. et al., Baculovirus 5 Expression Vectors: A Laboratory Manual, New York, Oxford University Press., 1994; and, Richardson, C. D., Ed., Baculovirus Expression Protocols. Methods in Molecular Biology, Totowa, NJ, Humana Press, 1995. A second method of making recombinant zsig45 baculovirus utilizes a 10 transposon-based system described by Luckow (Luckow, V.A, et al., J Virol 67:4566-79, 1993). This system, which utilizes transfer vectors, is sold in the Bac-to-BacTM kit (Life Technologies, Rockville, MD). This system utilizes a transfer vector, pFastBacl TM (Life Technologies) containing 15 a Tn7 transposon to move the DNA encoding the zsig45 polypeptide into a baculovirus genome maintained in E. coli as a large plasmid called a "bacmid." See, Hill Perkins, M.S. and Possee, R.D., J Gen Virol 71:971-6, 1990; Bonning, B.C. et al., J Gen Virol 75:1551-6, 1994; 20 and, Chazenbalk, G.D., and Rapoport, B., J Biol Chem 270:1543-9, 1995. In addition, transfer vectors can include an in-frame fusion with DNA encoding an epitope tag at the C- or N-terminus of the expressed zsig45 polypeptide, for example, a Glu-Glu epitope tag 25 (Grussenmeyer, T. et al., Proc. Natl. Acad. Sci. 82:7952 4, 1985). Using a technique known in the art, a transfer vector containing zsig45 is transformed into E. Coli, and screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid 30 DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect Spodoptera frugiperda cells, e.g. Sf9 cells. Recombinant virus that expresses zsig45 is subsequently produced.
WO99/28467 PCTIUS98/25454 41 Recombinant viral stocks are made by methods commonly used the art. The recombinant virus is used to infect host cells, typically a cell line derived from the fall 5 armyworm, Spodoptera frugiperda. See, in general, Glick and Pasternak, Molecular Biotechnology: Principles and Applications of Recombinant DNA, ASM Press, Washington, D.C., 1994. Another suitable cell line is the High FiveOTM cell line (Invitrogen) derived from Trichoplusia ni (U.S. 10 Patent No. 5,300,435). Commercially available serum-free media are used to grow and maintain the cells. Suitable media are Sf900 IITM (Life Technologies) or ESF 92 1 TM (Expression Systems) for the Sf9 cells; and Ex-cellO405TM (JRH Biosciences, Lenexa, KS) or Express FiveOTM (Life 15 Technologies) for the T. ni cells. The cells are grown up from an inoculation density of approximately 2-5 x l05 cells to a density of 1-2 x 106 cells at which time a recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to 10, more typically near 3. 20 Procedures used are generally described in available laboratory manuals (King, L. A. and Possee, R.D., ibid.; O'Reilly, D.R. et al., ibid.; Richardson, C. D., ibid.). Subsequent purification of the zsig45 polypeptide from the supernatant can be achieved using methods described 25 herein. Fungal cells, including yeast cells, can also be used within the present invention. Yeast species of particular interest in this regard include Saccharomyces 30 cerevisiae, Pichia pastoris, and Pichia methanolica. Methods for transforming S. cerevisiae cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S.
WO99/28467 PCT/US98/25454 42 Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformed cells are selected by 5 phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in Saccharomyces cerevisiae is the POT1 vector system disclosed by Kawasaki et al. (U.S. Patent 10 No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No. 15 4,615,974; and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454. Transformation systems for other yeasts, including Hansenula polymorpha, Schizosaccharomyces pombe, 20 Kluyveromyces lactis, Kluyveromyces fragilis, Ustilago maydis, Pichia pastoris, Pichia methanolica, Pichia guillermondii and Candida maltosa are known in the art. See, for example, Gleeson et al., J. Gen. Microbiol. 132:3459-3465, 1986 and Cregg, U.S. Patent No. 4,882,279. 25 Aspergillus cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming Acremonium chrysogenum are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming Neurospora are disclosed by Lambowitz, U.S. 30 Patent No. 4,486,533. The use of Pichia methanolica as host for the production of recombinant proteins is disclosed in WIPO Publications WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in transforming P.
WO99/28467 PCT/US98/25454 43 methanolica will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in P. methanolica, it is preferred that the promoter and 5 terminator in the plasmid be that of a P. methanolica gene, such as a P. methanolica alcohol utilization gene (AUG1 or AUG2). Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. To 10 facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment of the plasmid flanked at both ends by host DNA sequences. A preferred selectable marker for use in Pichia methanolica is a P. methanolica ADE2 gene, which 15 encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), which allows ade2 host cells to grow in the absence of adenine. For large-scale, industrial processes where it is desirable to minimize the use of methanol, it is preferred to use host cells in which both methanol 20 utilization genes (AUG1 and AUG2) are deleted. For production of secreted proteins, host cells deficient in vacuolar protease genes (PEP4 and PRB1) are preferred. Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of 25 interest into P. methanolica cells. It is preferred to transform P. methanolica cells by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant (t) of from 1 to 40 30 milliseconds, most preferably about 20 milliseconds. Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of WO99/28467 PCTIUS98/25454 44 suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as 5 growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co 10 transfected into the host cell. P. methanolica cells are cultured in a medium comprising adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25 0 C to 35 0 C. Liquid cultures are provided with sufficient aeration by conventional means, such as shaking 15 of small flasks or sparging of fermentors. A preferred culture medium for P. methanolica is YEPD (2% D-glucose, 2% BactoTM Peptone (Difco Laboratories, Detroit, MI), 1% BactoTM yeast extract (Difco Laboratories), 0.004% adenine and 0.006% L-leucine). 20 Prokaryotic host cells, including strains of the bacteria Escherichia coli, Bacillus and other genera are also useful host cells within the present invention. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the 25 art (see, e.g., Sambrook et al., ibid.). When expressing a zsig45 polypeptide in bacteria such as E. coli, the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former 30 case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea. The denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of WO99/28467 PCTIUS98/25454 45 reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the latter case, the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the 5 cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding. It is preferred to purify the polypeptides of 10 the present invention to 80% purity, more preferably to 90% purity, even more preferably 95% purity, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins 15 and nucleic acids, and free of infectious and pyrogenic agents. Preferably, a purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. Expressed recombinant zsig45 polypeptides 20 (including chimeric or fusion zsig45 polypeptides) can be purified using fractionation and/or conventional purification methods and media. Ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples. Exemplary purification 25 steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable chromatographic media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives 30 are preferred. Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl Sepharose (Pharmacia) and the like; or polyacrylic resins, WO99/28467 PCT/US98/25454 46 such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked 5 polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate 10 moieties. Examples of coupling chemistries include cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries. These and other 15 solid media are well known and widely used in the art, and are available from commercial suppliers. Methods for binding ligand or receptor polypeptides to support media are well known in the art. Selection of a particular method is a matter of routine design and is determined in 20 part by the properties of the chosen support. See, for example, Affinity Chromatography: Principles & Methods, Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988. The polypeptides of the present invention can be isolated by exploitation of their structural and 25 biological properties. For example, simple ion exchange chromatography and reverse-phase HPLC and/or gel permeation chromatography can be employed to purify a protein of this size and pI. Other methods may also be employed. For example, immobilized metal ion adsorption 30 (IMAC) chromatography can be used to purify histidine-rich proteins, including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to form a chelate (E. Sulkowski, Trends in Biochem. 3:1-7, 1985). Histidine-rich proteins will be adsorbed to this WO99/28467 PCTIUS98/25454 47 matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other methods of purification include purification of 5 glycosylated proteins by lectin affinity chromatography and ion exchange chromatography (Methods in Enzymol., Vol. 182, "Guide to Protein Purification", M. Deutscher, (ed.), Acad. Press, San Diego, 1990, pp.529-39). Within additional embodiments of the invention, a fusion of the 10 polypeptide of interest and an affinity tag (e.g., polyhistidine, maltose-binding protein, an immunoglobulin domain) may be constructed to facilitate purification. Moreover, using methods described in the art, polypeptide fusions, or hybrid zsig45 proteins, are 15 constructed using regions or domains of the inventive zsig45 polypeptide in combination with those of other human 2-19 family proteins (e.g. human 2-19, D87120, and murine EF-7), or heterologous proteins (Sambrook et al., ibid., Altschul et al., ibid., Picard. D. Cur. Opin. 20 Biology, 5:511-515, 1994, and references therein). These methods allow the determination of the biological importance of larger domains or regions in a polypeptide of interest. Such hybrids may alter reaction kinetics, binding, constrict or expand the substrate specificity, or 25 alter tissue and cellular localization of a polypeptide, and can be applied to polypeptides of unknown structure. Fusion polypeptides can be prepared by methods known to those skilled in the art by preparing each component of the fusion protein and chemically conjugating 30 them. Alternatively, a polynucleotide encoding one or more components of the fusion protein in the proper reading frame can be generated using known techniques and expressed by the methods described herein. For example, part or all of a domain(s) conferring a biological WO99/28467 PCT/US98/25454 48 function may be swapped between zsig45 of the present invention with the functionally equivalent domain(s) from another family member or heterologous protein. Such domains comprise but are not limited to the three 5 disclosed secretory signal sequences, the mature protein, and conserved motifs. Such fusion proteins would be expected to have a biological functional profile that is the same or similar to polypeptides of the present invention or to the proteins to which they are fused, 10 depending on the fusion constructed. Moreover, such fusion proteins may exhibit other properties as disclosed herein. Standard molecular biological and cloning techniques can be used to swap the equivalent domains 15 between the zsig45 polypeptide and those polypeptides to which they are fused. Generally, a DNA segment that encodes a domain of interest, e.g., a zsig45 domain described herein, is operably linked in frame to at least one other DNA segment encoding an additional polypeptide 20 (for instance an analogous domain or region human 2-19 protein), and inserted into an appropriate expression vector, as described herein. Generally DNA constructs are made such that the several DNA segments that encode the corresponding regions of a polypeptide are operably linked 25 in frame to make a single construct that encodes the entire fusion protein, or a functional portion thereof. For example, a DNA construct would encode from N-terminus to C-terminus a fusion protein comprising a signal polypeptide followed by a mature polypeptide; or a DNA 30 construct would encode from N-terminus to C-terminus a fusion protein comprising a signal polypeptide followed by regions comprising the motifs 1 through 5 in the order as they appear in the zsig45 polypeptide, or the equivalent regions from a heterologous protein, e.g. human 2-19, WO99/28467 PCT/US98/25454 49 protein. Such fusion proteins can be expressed, isolated, and assayed for activity as described herein. Zsig45 polypeptides or fragments thereof may also be prepared through chemical synthesis. Zsig45 5 polypeptides may be monomers or multimers; glycosylated or non-glycosylated; pegylated or non-pegylated; and may or may not include an initial methionine amino acid residue. The activity of molecules of the present 10 invention may be measured using a variety of assays that measure thyroid, cardiovascular and bone function. Of particular interest are metabolism, thyroid or pituitary hormone secretion, and bone resorption and formation assays. Such assays are well known in the art. 15 In view of the tissue distribution observed for this zsig45 polypeptide, agonists (including the natural receptor/ substrate/ cofactor/ etc.) and antagonists have enormous potential in both in vitro and in vivo applications. The zsig45 polypeptide, fragment thereof, 20 or compounds identified as zsig45 agonists, antagonists may be useful for promoting growth, proliferation or differentiation of various cell types in vitro and treatment of extrathyroid or thyroid disorders in vivo. For example, such compounds are useful as components of 25 defined cell culture media, and may be used alone or in combination with other cytokines and hormones to replace serum that is commonly used in cell culture. Within another embodiment, there is provided a method of identifying antagonists of zsig45 polypeptides, 30 comprising providing cells responsive to a zsig45 polypeptide, culturing a first portion of the cells in the presence of a test compound, culturing a second portion of the cells in the absence of a test compound, and detecting an increase in a cellular response of the first portion of WO99/28467 PCT/US98/25454 50 the cells as compared to the second portion of the cells. Within another embodiment, there is provided a method of identifying antagonists of zsig45 polypeptide, comprising providing cells responsive to a zsig45 polypeptide, 5 culturing a first portion of the cells in the presence of zsig45 polypeptide, culturing a second portion of the cells in the presence of the zsig45 polypeptide and a test compound, and detecting a decrease in a cellular response of the second portion of the cells as compared to the 10 first portion of the cells. Molecules of the present invention can be used to identify and isolate receptors involved in thyroid, pituitary, cardiac or other function, to which zsig45 polypeptides bind in vivo. For example, proteins and 15 peptides of the present invention can be immobilized on a column and membrane preparations run over the column (Immobilized Affinity Ligand Techniques, Hermanson et al., eds., Academic Press, San Diego, CA, 1992, 195-202). Proteins and peptides can also be radiolabeled (Methods in 20 Enzymol., vol. 182, "Guide to Protein Purification", M. Deutscher, ed., Acad. Press, San Diego, 1990, 721-737) or photoaffinity labeled (Brunner et al., Ann. Rev. Biochem. 62:483-514, 1993 and Fedan et al., Biochem. Pharmacol 33:1167-1180, 1984) and specific cell-surface proteins can 25 be identified. As a ligand, the activity of zsig45 polypeptide can be measured by a silicon-based biosensor microphysiometer which measures the extracellular acidification rate or proton excretion associated with 30 receptor binding and subsequent physiologic cellular responses. An exemplary device is the Cytosensor T M Microphysiometer manufactured by Molecular Devices, Sunnyvale, CA. A variety of cellular responses, such as cell proliferation, ion transport, energy production, WO99/28467 PCT/US98/25454 51 inflammatory response, regulatory and receptor activation, and the like, can be measured by this method. See, for example, McConnell, H.M. et al., Science 257:1906-1912, 1992; Pitchford, S. et al., Meth. Enzymol. 228:84-108, 5 1997; Arimilli, S. et al., J. Immunol. Meth. 212:49-59, 1998; Van Liefde, I. et al., Eur. J. Pharmacol. 346:87-95, 1998. The microphysiometer can be used for assaying adherent or non-adherent eukaryotic or prokaryotic cells. By measuring extracellular acidification changes in cell 10 media over time, the microphysiometer directly measures cellular responses to various stimuli, including zsig45 polypeptide, its agonists, or antagonists. Preferably, the microphysiometer is used to measure responses of a zsig45-responsive eukaryotic cell, compared to a control 15 eukaryotic cell that does not respond to zsig45 polypeptide. ZSIG45-responsive eukaryotic cells comprise cells into which a receptor for zsig45 has been transfected creating a cell that is responsive to zsig45; or cells naturally responsive to zsig45 such as cells 20 derived from thyriod, heart, pituitary, hypothalmic, bone, bione marrow and skelital muscle tissues amongst others. Differences, measured by a change, for example, an increase or diminution in extracellular acidification, in the response of cells exposed to zsig45 polypeptide, 25 relative to a control not exposed to zsig45, are a direct measurement of zsig45-modulated cellular responses. Moreover, such zsig45-modulated responses can be assayed under a variety of stimuli. Using the microphysiometer, there is provided a method of identifying agonists of 30 zsig45 polypeptide, comprising providing cells responsive to a zsig45 polypeptide, culturing a first portion of the cells in the absence of a test compound, culturing a second portion of the cells in the presence of a test compound, and detecting a change, for example, an increase WO99/28467 PCTIUS98/25454 52 or diminution, in a cellular response of the second portion of the cells as compared to the first portion of the cells. The change in cellular response is shown as a measurable change extracellular acidification rate. 5 Moreover, culturing a third portion of the cells in the presence of zsig45 polypeptide and the absence of a test compound can be used as a positive control for the zsig45 responsive cells, and as a control to compare the agonist activity of a test compound with that of the zsig45 10 polypeptide. Moreover, using the microphysiometer, there is provided a method of identifying antagonists of zsig45 polypeptide, comprising providing cells responsive to a zsig45 polypeptide, culturing a first portion of the cells in the presence of zsig45 and the absence of a test 15 compound, culturing a second portion of the cells in the presence of zsig45 and the presence of a test compound, and detecting a change, for example, an increase or a diminution in a cellular response of the second portion of the cells as compared to the first portion of the cells. 20 The change in cellular response is shown as a measurable change extracellular acidification rate. Antagonists and agonists, for zsig45 polypeptide, can be rapidly identified using this method. Moreover, zsig45 can be used to identify cells, 25 tissues, or cell lines which respond to a zsig45 stimulated pathway. The microphysiometer, described above, can be used to rapidly identify ligand-responsive cells, such as cells responsive to zsig45 of the present invention. Cells can be cultured in the presence or 30 absence of zsig45 polypeptide. Those cells which elicit a measurable change in extracellular acidification in the presence of zsig45 are responsive to zsig45. Such cell lines, can be used to identify antagonists and agonists of zsig45 polypeptide as described above.
WO99/28467 PCT/US98/25454 53 The polypeptides, nucleic acid and/or antibodies of the present invention may be used in treatment of disorders associated with thyroid dysfunction. The molecules of the present invention can be used to treat or 5 prevent development of pathological conditions in such diverse tissue as thyroid, heart and bone. In particular, certain syndromes an diseases may be amenable to such diagnosis, treatment or prevention, such as thyroid disorders, ischemia reperfusion injury, inflammatory 10 disorders, amongst others disclosed herein. The activity of molecules of the present invention can be measured using a variety of assays that measure, for example, signal transduction upon binding a receptor, thyroid hormone secretion in vitro and in vivo, 15 bone loss, TSH activity, or antibody binding. For example, zsig45 polypeptides can be labeled and tested for specific and saturating binding to specific cell lines or cells. Identification of positive cells to which zsig45 binds can be achieved by injecting a radioactively or 20 fluorescently-labeled zsig45 polypeptide and using art recognized immunohistochemistry methods to visualize a cell or tissue in vivo where zsig45 binds. After identification of positive cells to which zsig45 binds, activity can be tested for zsig45-mediated activation of a 25 signal transduction pathway using methods known in the art. For instance, vector constructs containing a reporter (e.g. SRE-luciferase, STAT-luciferase, thyroid hormone response element (THRE)-luciferase or the like) can be introduced into the positive cell lines; such cell 30 lines, when exposed to conditioned media containing secreted zsig45 protein, will demonstrate zsig45-mediated signal transduction activity through activation of the measurable reporter. Such assays are well known in the WO99/28467 PCT/US98/25454 54 art. Specific assays include, but are not limited to, bioassays measuring signal transduction. The molecules of the present invention may exert their effects in thyroid or extrathyroidally. Thus, 5 activity of zsig45 polypeptides, agonists or antagonists, may affect thyroid function and can be measured by assessing thyroid hormone secretion in vitro or thyroid function in vivo. Thyroid hormones, and changes in thyroid hormone secretion in the presence or absence of 10 zsig45, may be detected using various methods known in the art. For example, TSH and other thyroid hormones are commonly measured by radioimmune assay (RIA), immunometric assays (IMA) employing a "sandwich" type assay, or ELISA. Hormones, including T3 and T4, may be measured in vivo by 15 a variety of methods known in the art (Elkins, R., Endocr. Rev., 11:5-46, 1990). For example, T4 may be measured using a radiometric 125I binding assay, dialysis and ultrafiltration. See Braverman, L.E. (Ed.), ibid., p.35 48. 20 In addition, the zsig45 polypeptide, agonists or antagonists, of the present invention may modulate the plasma membrane protein, iodothyrone 5'-monodeiodinase type-II (5'D-II), which peripherally converts T4 to T3. Such effects can be measured indirectly in vivo by 25 assessing T4 or T3 as discussed herein, or directly in vitro by measuring 5'D-II enzyme activity. Moreover, the effects of T3 clearance in liver by 5'-deiodinase type I(5'D-I) can be assessed in vivo. See Braverman, L.E. (Ed.), ibid., p.49-68. 30 Moreover, in vivo affects of zsig45 polypeptides on thyroid function can also be assessed in experimental animals or humans by ultrasound, radioactive iodine uptake, and fine needle aspiration biopsy (Braverman, L.E. (Ed.), ibid., p.35-48).
WO99/28467 PCT/US98/25454 55 Thyroid malfunction and some of the currently associated therapies can elicit detrimental effects on bone in vivo. Thus, given the thyroidal and pituitary 5 localization of the present invention, assays that measure bone formation and/or resorption are important assays to assess zsig45 activity. One example is an assay system that permits rapid identification of substances having selective calcitonin receptor activity on cells expressing 10 the calcitonin receptor. The calcitonin receptor is a member of the G-protein receptor family and transduces signal via activation of adenylate cyclase, leading to elevation of cellular cAMP levels (Lin et al., Science 254:1022-24, 1991). This assay system exploits the 15 receptor's ability to elevate cAMP levels as a way to detect other molecules that are able to stimulate the calcitonin receptor and initiate signal transduction. Other assays that measure bone formation or resorption include calvarial assays, QCT, and assays that measure 20 osteoblast size and number. Such assays are known in the art and discussed below. Receptor activation can be detected by: (1) measurement of adenylate cyclase activity (Salomon et al., Anal. Biochem. 58:541-48, 1974; Alvarez and Daniels, Anal. 25 Biochem. 187:98-103, 1990); (2) measurement of change in intracellular cAMP levels using conventional radioimmunoassay methods (Steiner et al., J. Biol. Chem. 247:1106-13, 1972; Harper and Brooker, J. Cyc. Nucl. Res. 1:207-18, 1975); or (3) through use of a cAMP 30 scintillation proximity assay (SPA) method (Amersham Corp., Arlington Heights, IL). While these methods provide sensitivity and accuracy, they involve considerable sample processing prior to assay, are time WO99/28467 PCTIUS98/25454 56 consuming, involve the use of radioisotopes, and would be cumbersome for large scale screening assays. An alternative assay system involves selection of polypeptides that are able to induce expression of a 5 cyclic AMP response element (CRE)-luciferase reporter gene, as a consequence of elevated cAMP levels, in cells expressing a calcitonin receptor, but not in cells lacking calcitonin receptor expression, as described in U.S. patent No. 5,622,839, U.S. Patent No. 5,674,689, and U.S. 10 patent No. 5,674,981. Well established animal models are available to test in vivo efficacy of zsig45 polypeptides, agonists or antagonists, that interact with the calcitonin receptor. Moreover, these models may be used to test effects of 15 zsig45 on bone other than through the calcitonin receptor. For example, the hypocalcemic rat or mouse model can be used to determine the effect on serum calcium, and the ovariectomized rat or mouse can be used as a model system for osteoporosis. Bone changes seen in these models and 20 in humans during the early stages of estrogen deficiency are qualitatively similar. Calcitonin has been shown to be an effective agent for the prevention of bone loss in ovariectomized women and rats (Mazzuoli et al., Calcif. Tissue Int. 47:209-14, 1990; Wronski et al., Endocrinology 25 129:2246-50, 1991). High dose estrogen has been shown to inhibit bone resorption and to stimulate bone formation in an ovariectomized mouse model (Bain et al., J. Bone Miner. Res. 8:435-42, 1993). Biologically active zsig45 polypeptides, 30 agonists or antagonists, of the present invention that interact with the calcitonin receptor, or exert other effects on bone, are therefore contemplated to be advantageous for use in therapeutic applications for which calcitonin is useful. Such applications, for example, are WO99/28467 PCT/US98/25454 57 in the treatment of osteoporosis, Paget's disease, hyperparathyroidism, osteomalacia, idiopathic hypercalcemia of infancy and other conditions. Additional applications are to inhibit gastric secretion in the 5 treatment of acute pancreatitis and gastrointestinal disorders, and uses as analgesics, in particular for bone pain. In vivo assays for measuring changes in bone formation rates include performing bone histology (see, 10 Recker, R., eds. Bone Histomorphometry: Techniques and Interpretation. Boca Raton: CRC Press, Inc., 1983) and quantitative computed tomography (QCT; Ferretti,J. Bone 17:353S-364S, 1995; Orphanoludakis et al., Investig. Radiol. 14:122-130, 1979; and Durand et al., Medical 15 Physics 19:569-573, 1992). An exemplary ex vivo assay for measuring changes in bone formation is a calavarial assay (Gowen et al., J. Immunol. 136:2478-2482, 1986) or resorption calvarial assay (Linkhart, T.A., and Mohan, S., Endocrinology 125:1484-1491, 1989). 20 In addition, polypeptides of the present invention can be assayed and used for their ability to modify inflammation. Methods to determine proinflammatory and antiinflammatory qualities of zsig45 are known in the art and discussed herein. For example, suppression of 25 cAMP production is an indication of anti-inflammatory effects (Nihei, Y., et al., Arch. Dermatol. Res., 287:546 552, 1995). Suppression of cAMP and inhibition of ICAM and HLA-Dr induced by IFN-y in keratinocytes can be used to assess inhibition of inflammation. Alternatively, 30 enhancement of cAMP production and induction of ICAM and HLA-Dr in this system can be an measurement of proinflammatory effects of a protein. Zsig45, likewise can exhibit similar inflammatory effects, as shown in vivo (Example 8) and may exert these effects in tissues in WO99/28467 PCT/US98/25454 58 which it is expressed, or in other tissues. For example, zsig45 is expressed in the colon, and can be useful in promoting wound healing in this tissue, or exhibit anti bacterial or anti-viral effects. Moreover, zsig45 or its 5 antagonists can be useful in treatment of inflammatory bowel disease, diverticulitis, inflammation during and after intestinal surgery, and the like. In addition, zsig45, expressed in thyroid, can have wound-healing or antimicrobial or antiviral actions in tissues outside of 10 thyroid, such, as heart, brain, liver, kidney, and the like. Moreover, direct measurement of zsig45 polypeptide and zsig45 antibodies can be useful in diagnosing inflammatory diseases such as melanoma, inflammatory bowel disease, diverticulitis, asthma, pelvic inflammatory 15 disease, (PID), psoriasis, arthritis, reperfusion ischemia, and other inflammatory diseases. Moreover zsig45, antagonists can be useful in treatment of myocarditis, atherosclerosis, pelvic inflammatory disease, (PID), psoriasis, arthritis, eczema, scleroderma, and 20 other inflammatory diseases. As such, zsig45 polypeptide, agonists or its antagonists, have potential uses in inflammatory diseases such as asthma and arthritis. For example, if zsig45 is proinflammatory, antagonists would be valuable in asthma 25 therapy or other anti-inflammatory therapies where migration of lymphocytes is damaging. In addition, zsig45 can serve other important roles in lung function, for instance, bronchodilation, tissue elasticity, recruitment of lymphocytes in lung infection and damage. Assays to 30 assess the activity of zsig45 in lung cells are discussed in Laberge, S. et al., Am. J. Respir. Cell Mol. Biol. 17:193-202, 1997; Rumsaeng, V. et al., J. Immunol., 159:2904-2910, 1997; and Schluesener, H.J. et al., J. Neurosci. Res. 44:606-611, 1996. Methods to determine WO99/28467 PCTIUS98/25454 59 proinflammatory and antiinflammatory qualities of zsig45 its agonists or its antagonists are known in the art. Moreover, other molecular biological, immunological, and biochemical techniques known in the art and disclosed 5 herein can be used to determine zsig45 activity and to isolate agonists and antagonists. Moreover, based on high expression in thyriod, zsig45 polypeptide may exhibit antiviral activity by inhibiting viral replication by specific signaling via 10 it's receptor(s) on a host cell (e.g. T-cell). Zsig45 can exhibit immune cell proliferative activity (See, example 8), can be assayed for this activity as disclosed herein, and may stimulate the immune system to fight viral infections. Moreover, zsig45 may bind CD4 or another 15 lymphocyte receptor and exhibit antiviral effects, for example, against human immunodeficiency virus (HIV) or human T-cell lymphotropic virus (HTLV). Alternatively, zsig45 polypeptide may compete for a viral receptor or co receptor to block viral infection. Zsig45 may be given 20 parentally to prevent viral infection or to reduce ongoing viral replication and re-infection (Gayowski, T. et al., Transplantation 64:422-426, 1997). Thus, zsig45 may be used as an antiviral therapeutic, for example, for viral leukemias (HTLV), AIDS (HIV), or gastrointestinal viral 25 infections caused by, for example, rotavirus, calicivirus (e.g., Norwalk Agent) and certain strains of pathogenic adenovirus. Both zsig45 modulated direct and indirect inflammation can be assayed by methods in the art. Foe 30 example see, Hamada, T. et al. J. Exp. Med. 188:539-548, 1998; and Liu, L. et al., J. Immunol. 161:3064-3070, 1998. For example, proinflammatory effects of zsig45 polypeptide can be directly tested in assays using a TranswellTM (Costar), wherein endothelial cells are plated on a semi- WO99/28467 PCTIUS98/25454 60 permeable membrane and zsig45 polypeptide is present in the lower chamber of the transwell and Crs 1 or fluorescently-labeled neutrophils (PMNs), lymphocytes, HL60 cells, K562 cells, or the like are added on to the 5 upper chamber of the transwell. Migration of the PMNs and the like to the lower chamber of the transwell in the presence of zsig45 polypeptide, but not its absence (Negative control), would demonstrate zsig45 polypeptide as a direct chemoattractant of the PMNs. Moreover, IL-8 10 could be employed in this assay as a positive control. To test zsig45 as indirect stimulator of inflammatory response, a similar method can be employed. For example, an experiment can be set up as per above where in addition to the presence of zsig45 on the lower chamber of the 15 transwell, fibroblast or adipocytes are plated there. In this way, effects of zsig45 polypeptide in inducing these cells to secrete factors that enhance migration of PMNs, i.e., inflammation, can be measured. The bFGF can be used as a positive control for indirect assay. Anti 20 inflammatory effects of zsig45 polypeptide can also be measured when added on the upper chamber in the presence of PMN's using a similar transwell assay known in the art. The activity of molecules of the present invention may be measured using a variety of assays that, 25 for example, measure neogenesis or hyperplasia (i.e., proliferation) of cardiac cells based on the potential effects of extrathyroidal activity of zsig45. Additional activities likely associated with the polypeptides of the present invention include proliferation of endothelial 30 cells, cardiomyocytes, fibroblasts, skeletal myocytes directly or indirectly through other growth factors; action as a chemotaxic factor for endothelial cells, fibroblasts and/or phagocytic cells; osteogenic factor; WO99/28467 PCT/US98/25454 61 and factor for expanding mesenchymal stem cell and precursor populations. Proliferation can be measured using cultured cardiac cells or in vivo by administering molecules of the 5 present invention to the appropriate animal model. Generally, proliferative effects are seen as an increase in cell number, and may include inhibition of apoptosis as well as stimulation of mitogenesis. Cultured cells for use in these assays include cardiac fibroblasts, cardiac 10 myocytes, skeletal myocytes, and human umbilical vein endothelial cells from primary cultures. Suitable established cell lines include: NIH 3T3 fibroblasts (ATCC No. CRL-1658), CHH-1 chum heart cells (ATCC No. CRL-1680), H9c2 rat heart myoblasts (ATCC No. CRL-1446), Shionogi 15 mammary carcinoma cells (Tanaka et al., Proc. Natl. Acad. Sci. 89:8928-8932, 1992), and LNCap.FGC adenocarcinoma cells (ATCC No. CRL-1740.) Assays measuring cell proliferation are well known in the art. For example, assays measuring proliferation include such assays as 20 chemosensitivity to neutral red dye (Cavanaugh et al., Investigational New Drugs 8:347-354, 1990), incorporation of radiolabeled nucleotides (Cook et al., Analytical Biochem. 179:1-7, 1989), incorporation of 5-bromo-2' deoxyuridine (BrdU) in the DNA of proliferating cells 25 (Porstmann et al., J. Immunol. Methods 82:169-179, 1985), and use of tetrazolium salts (Mosmann, J. Immunol. Methods 65:55-63, 1983; Alley et al., Cancer Res. 48:589-601, 1988; Marshall et al., Growth Reg. 5:69-84, 1995; and Scudiero et al., Cancer Res. 48:4827-4833, 1988). 30 Differentiation is a progressive and dynamic process, beginning with pluripotent stem cells and ending with terminally differentiated cells. Pluripotent stem cells that can regenerate without commitment to a lineage express a set of differentiation markers that are lost WO99/28467 PCTIUS98/25454 62 when commitment to a cell lineage is made. Progenitor cells express a set of differentiation markers that may or may not continue to be expressed as the cells progress down the cell lineage pathway toward maturation. 5 Differentiation markers that are expressed exclusively by mature cells are usually functional properties such as cell products, enzymes to produce cell products, and receptors. The stage of a cell population's differentiation is monitored by identification of markers 10 present in the cell population. Myocytes, osteoblasts, adipocytes, chrondrocytes, fibroblasts and reticular cells are believed to originate from a common mesenchymal stem cell (Owen et al., Ciba Fdn. Symp. 136:42-46, 1988). Markers for mesenchymal stem cells have not been well 15 identified (Owen et al., J. of Cell Sci. 87:731-738, 1987), so identification is usually made at the progenitor and mature cell stages. The existence of early stage cardiac myocyte progenitor cells (often referred to as cardiac myocyte stem cells) has been speculated, but not 20 demonstrated, in adult cardiac tissue. The novel polypeptides of the present invention may be useful for studies to isolate mesenchymal stem cells and cardiac myocyte progenitor cells, both in vivo and ex vivo. There is evidence to suggest that factors that 25 stimulate specific cell types down a pathway towards terminal differentiation or dedifferentiation affect the entire cell population originating from a common precursor or stem cell. Thus, the present invention includes stimulating or inhibiting the proliferation of myocytes, 30 smooth muscle cells, osteoblasts, adipocytes, chrondrocytes and endothelial cells. Molecules of the present invention may, while stimulating proliferation or differentiation of cardiac myocytes, inhibit proliferation or differentiation of adipocytes, by virtue of the affect WO99/28467 PCT/US98/25454 63 on their common precursor/stem cells. Thus molecules of the present invention may have use in inhibiting chondrosarcomas, atherosclerosis, restenosis and obesity. Assays measuring differentiation include, for 5 example, measuring cell-surface markers associated with stage-specific expression of a tissue, enzymatic activity, functional activity or morphological changes (Watt, FASEB, 5:281-284, 1991; Francis, Differentiation 57:63-75, 1994; Raes, Adv. Anim. Cell Biol. Technol. Bioprocesses, 161 10 171, 1989; all incorporated herein by reference). In vivo assays for evaluating cardiac neogenesis or hyperplasia include treating neonatal and mature rats with the molecules of the present invention. The animals' cardiac function is measured as heart rate, blood 15 pressure, and cardiac output to determine left ventricular function. Post-mortem methods for assessing cardiac decline or improvement include: increased or decreased cardiac weight, nuclei/cytoplasmic volume, and staining of cardiac histology sections to determine proliferating cell 20 nuclear antigen (PCNA) vs. cytoplasmic actin levels (Quaini et al., Circulation Res. 75:1050-1063, 1994 and Reiss et al., Proc. Natl. Acad. Sci. 93:8630-8635, 1996.) Zsig45 polypeptides can also be used to prepare antibodies that specifically bind to zsig45 epitopes, 25 peptides or polypeptides. The zsig45 polypeptide or a fragment thereof serves as an antigen (immunogen) to inoculate an animal and elicit an immune response. One of skill in the art would recognize that antigens or immunogenic epitopes can consist of stretches of amino 30 acids within a longer polypeptide from less than about 10 amino acids or longer, and up to about the entire length of the polypeptide or longer depending on the polypeptide. Suitable antigens include the zsig45 polypeptide encoded by SEQ ID NO:2 from amino acid number 47 (Lys) to amino WO99/28467 PCTIUS98/25454 64 acid number 114 (Asp), or a contiguous 9 to 67 amino acid fragment thereof. Preferred peptides to use as antigens are hydrophilic peptides such as those predicted by one of skill in the art from a hydrophobicity plot, determined 5 for example, from a Hopp/Woods hydrophilicity profile based on a sliding six-residue window, with buried G, S, and T residues and exposed H, Y, and W residues ignored, or from the hydrophilic domains, motifs 1 through 5, or regions between motifs 1 through 5 disclosed herein. 10 Antibodies generated from this immune response can be isolated and purified as described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, Current Protocols in Immunology, Cooligan, et al. (eds.), 15 National Institutes of Health, John Wiley and Sons, Inc., 1995; Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, 1989; and Hurrell, J. G. R., Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Inc., Boca Raton, 20 FL, 1982. As would be evident to one of ordinary skill in the art, antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with 25 a zsig45 polypeptide or a fragment thereof. The immunogenicity of a zsig45 polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion 30 polypeptides, such as fusions of zsig45 or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion may be 35 advantageously joined or linked to a macromolecular WO99/28467 PCTIUS98/25454 65 carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization. As used herein, the term "antibodies" includes polyclonal antibodies, affinity-purified polyclonal 5 antibodies, monoclonal antibodies, and antigen-binding fragments, such as F(ab') 2 and Fab proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen 10 binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by 15 replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, 20 biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced. Alternative techniques for generating or selecting antibodies useful herein include in vitro 25 exposure of lymphocytes to zsig45 protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled zsig45 protein or peptide). Genes encoding polypeptides having potential zsig45 polypeptide binding 30 domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as E. coli. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide WO99/28467 PCT/US98/25454 66 synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic 5 macromolecule, or organic or inorganic substances. Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al., US Patent NO. 5,223,409; Ladner et al., US Patent NO. 4,946,778; Ladner et al., US Patent NO. 5,403,484 and 10 Ladner et al., US Patent NO. 5,571,698) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from Clontech (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA) and Pharmacia LKB 15 Biotechnology Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the zsig45 sequences disclosed herein to identify proteins which bind to zsig45. These "binding proteins" which interact with zsig45 polypeptides can be used for tagging cells; for 20 isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like. These binding proteins can also be used in analytical methods such as for screening expression libraries and neutralizing 25 activity. The binding proteins can also be used for diagnostic assays for determining circulating levels of polypeptides; for detecting or quantitating soluble polypeptides as marker of underlying pathology or disease. These binding proteins can also act as zsig45 30 "antagonists" to block zsig45 binding and signal transduction in vitro and in vivo. These anti-zsig45 binding proteins would be useful for inhibiting inflammation or other zsig45 activity. Antibodies are determined to be specifically 35 binding if: 1) they exhibit a threshold level of binding activity, and/or 2) they do not significantly cross-react WO99/28467 PCT/US98/25454 67 with related polypeptide molecules. First, antibodies herein specifically bind if they bind to a zsig45 polypeptide, peptide or epitope with an affinity at least 10-fold greater than the binding affinity to control (non 5 zsig45) polypeptide. It is preferred that the antibodies exhibit a binding affinity (Ka) of 106 M
-
1 or greater, preferably 107 M
-
1 or greater, more preferably 10 M - or greater, and most preferably 10 M
-
1 or greater. The binding affinity of an antibody can be readily determined 10 by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci. 51: 660-672, 1949). Second, antibodies are determined to specifically bind if they do not significantly cross-react 15 with related polypeptides. Antibodies do not significantly cross-react with related polypeptide molecules, for example, if they detect zsig45 but not known related polypeptides using a standard Western blot analysis (Ausubel et al., ibid.). Examples of known related 20 polypeptides are orthologs, proteins from the same species that are members of a protein family (e.g. IL-16), zsig45 polypeptides, and non-human zsig45. Moreover, antibodies may be "screened against" known related polypeptides to isolate a population that specifically binds to the 25 inventive polypeptides. For example, antibodies raised to zsig45 are adsorbed to related polypeptides adhered to insoluble matrix; antibodies specific to zsig45 will flow through the matrix under the proper buffer conditions. Such screening allows isolation of polyclonal and 30 monoclonal antibodies non-crossreactive to closely related polypeptides (Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; Current Protocols in Immunology, Cooligan, et al. (eds.), WO99/28467 PCTIUS98/25454 68 National Institutes of Health, John Wiley and Sons, Inc., 1995). Screening and isolation of specific antibodies is well known in the art. See, Fundamental Immunology, Paul (eds.), Raven Press, 1993; Getzoff et al., Adv. in 5 Immunol. 43: 1-98, 1988; Monoclonal Antibodies: Principles and Practice, Goding, J.W. (eds.), Academic Press Ltd., 1996; Benjamin et al., Ann. Rev. Immunol. 2: 67-101, 1984. A variety of assays known to those skilled in 10 the art can be utilized to detect antibodies which specifically bind to zsig45 proteins or peptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of 15 such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmuno-precipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for 20 binding to wild-type versus mutant zsig45 protein or polypeptide. Antibodies to zsig45 may be used for tagging cells that express zsig45; for isolating zsig45 by affinity purification; for diagnostic assays for 25 determining circulating levels of zsig45 polypeptides; for detecting or quantitating soluble zsig45 as marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing 30 antibodies or as antagonists to block zsig45 activity in vitro and in vivo. Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may WO99/28467 PCTIUS98/25454 69 feature use of biotin-avidin or other complement/anti complement pairs as intermediates. Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates 5 used for in vivo diagnostic or therapeutic applications. Moreover, antibodies to zsig45 or fragments thereof may be used in vitro to detect denatured zsig45 or fragments thereof in assays, for example, Western Blots or other assays known in the art. 10 Molecules of the present invention can be used to identify and isolate receptors involved in thyroid, pituitary, cardiac or other function, to which zsig45 polypeptides bind in vivo. For example, proteins and peptides of the present invention can be immobilized on a 15 column and membrane preparations run over the column (Immobilized Affinity Ligand Techniques, Hermanson et al., eds., Academic Press, San Diego, CA, 1992, pp. 195-202). Proteins and peptides can also be radiolabeled (Methods in Enzymol., vol. 182, "Guide to Protein Purification", M. 20 Deutscher, ed., Acad. Press, San Diego, 1990, 721-737) or photoaffinity labeled (Brunner et al., Ann. Rev. Biochem. 62:483-514, 1993 and Fedan et al., Biochem. Pharmacol. 33:1167-1180, 1984) and specific cell-surface proteins can be identified. 25 Moreover, methods described above may be used to isolate anti-zsig45 binding proteins. Such antagonists can be isolated and used for treatment, for example, in rhabdomyosarcoma, cardiac myxoma, bone cancers of osteoblast origin, and dwarfism, arthritis, ligament and 30 cartilage repair, alone or combination with other therapies. The molecules of the present invention may be useful for elucidation and prevention of various thyroid diseases, bone diseases, menstrual problems, heart WO99/28467 PCT/US98/25454 70 diseases, bone, colon, pituitary and thyroid cancers. The polypeptides, nucleic acid and/or antibodies of the present invention may be used in treatment of disorders associated with thyroid dysfunction. The molecules of the 5 present invention may used to modulate thyroid activity or to treat or prevent development of pathological conditions in such diverse tissue as thyroid, heart and bone. In particular, certain syndromes and diseases may be amenable to such diagnosis, treatment or prevention. 10 The present invention also provides methods of studying mammalian cellular metabolism. Such methods of the present invention comprise incubating cells to be studied, for example, human vascular endothelial cells, ± 15 zsig45 polypeptide, monoclonal antibody, agonist or antagonist thereof and observing changes in adipogenesis, gluconeogenesis, glycogenolysis, lipogenesis, glucose uptake, or the like. Within another aspect of the present invention 20 there is provided a pharmaceutical composition comprising a purified zsig45 polypeptide in combination with a pharmaceutically acceptable vehicle. This pharmaceutical composition may be used to modulate energy balance in mammals or to protect endothelial cells from injury.. 25 Antibodies or polypeptides herein can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for in vivo diagnostic or therapeutic applications. For instance, polypeptides or antibodies of the present 30 invention can be used to identify or treat tissues or organs that express a corresponding anti-complementary molecule (receptor or antigen, respectively, for instance). More specifically, zsig45 polypeptides or anti-zsig45 antibodies, or bioactive fragments or portions WO99/28467 PCTIUS98/25454 71 thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the anti-complementary molecule. Suitable detectable molecules may be directly or 5 indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly attached to the 10 polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, Pseudomonas exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide 15 or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule 20 can be conjugated with a member of a complementary/ anticomplementary pair, where the other member is bound to the polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/ anticomplementary pair. 25 In another embodiment, polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Alternatively, if the polypeptide has multiple functional 30 domains (i.e., an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of WO99/28467 PCT/US98/25454 72 interest. In instances where the domain only fusion protein includes a complementary molecule, the anti complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule 5 fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anti complementary-detectable/ cytotoxic molecule conjugates. In another embodiment, zsig45-cytokine fusion proteins or antibody-cytokine fusion proteins can be used 10 for enhancing in vivo killing of target tissues (for example, blood and bone marrow cancers), if the zsig45 polypeptide or anti-zsig45 antibody targets the hyperproliferative blood or bone marrow cell (See, generally, Hornick et al., Blood 89:4437-47, 1997). 15 Hornick et al. described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine. Suitable zsig45 polypeptides or anti-zsig45 antibodies target an undesirable cell or tissue (i.e., a tumor or a 20 leukemia), and the fused cytokine mediated improved target cell lysis by effector cells. Suitable cytokines for this purpose include interleukin 2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), for instance. In yet another embodiment, the zsig45 25 polypeptide or anti- zsig45 antibody can target vascular cells or tissues. Such polypeptide or antibody can be conjugated with a radionuclide, and particularly with a beta-emitting radionuclide, to reduce restenosis. Such therapeutic approach poses less danger to clinicians who 30 administer the radioactive therapy. For instance, iridium-192 impregnated ribbons placed into stented vessels of patients until the required radiation dose was delivered showed decreased tissue growth in the vessel and greater luminal diameter than the control group, which WO99/28467 PCT/US98/25454 73 received placebo ribbons. Further, revascularisation and stent thrombosis were significantly lower in the treatment group. Similar results are predicted with targeting of a bioactive conjugate containing a radionuclide, as 5 described herein. The bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action. 10 Moreover, methods described above may be used to isolate anti-zsig45 binding proteins. Such antagonists can be isolated and used for treatment, for example, in rhabdomyosarcoma, cardiac myxoma, bone cancers of 15 osteoblast origin, and dwarfism, arthritis, ligament and cartilage repair, alone or combination with other therapies. The molecules of the present invention may be useful for elucidation and prevention of various thyroid 20 diseases, inflammation, bone diseases, menstrual problems, heart diseases, bone, colon, pituitary and thyroid cancers. n may used to modulate thyroid Polynucleotides encoding zsig45 polypeptides are useful within gene therapy applications where it is 25 desired to increase or inhibit zsig45 activity. If a mammal has a mutated or absent zsig45 gene, the zsig45 gene can be introduced into the cells of the mammal. In one embodiment, a gene encoding a zsig45 polypeptide is introduced in vivo in a viral vector. Such vectors 30 include an attenuated or defective DNA virus, such as, but not limited to, herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, retroviruses, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack WO99/28467 PCTIUS98/25454 74 viral genes, are preferred. A defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the 5 vector can infect other cells. Examples of particular vectors include, but are not limited to, a defective herpes simplex virus 1 (HSV1) vector (Kaplitt et al., Molec. Cell. Neurosci. 2:320-30, 1991); an attenuated adenovirus vector, such as the vector described by 10 Stratford-Perricaudet et al., J. Clin. Invest. 90:626-30, 1992; and a defective adeno-associated virus vector (Samulski et al., J. Virol. 61:3096-101, 1987; Samulski et al., J. Virol. 63:3822-8, 1989). In another embodiment, a zsig45 gene can be 15 introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al. Cell 33:153, 1983; Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No. 4,980,289; Markowitz et al., J. Virol. 62:1120, 1988; Temin et al., 20 U.S. Patent No. 5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995 by Dougherty et al.; and Kuo et al., Blood 82:845, 1993. Alternatively, the vector can be introduced by lipofection in vivo using liposomes. Synthetic cationic lipids can be 25 used to prepare liposomes for in vivo transfection of a gene encoding a marker (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7, 1987; Mackey et al., Proc. Natl. Acad. Sci. USA 85:8027-31, 1988). The use of lipofection to introduce exogenous genes into specific organs in vivo has 30 certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. More particularly, directing transfection to particular cells represents one area of benefit. For instance, directing transfection to particular cell types WO99/28467 PCT/US98/25454 75 would be particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, and brain. Lipids may be chemically coupled to other molecules for the purpose of targeting. Targeted 5 peptides (e.g., hormones or neurotransmitters), proteins such as antibodies, or non-peptide molecules can be coupled to liposomes chemically. It is possible to remove the target cells from the body; to introduce the vector as a naked DNA plasmid; 10 and then to re-implant the transformed cells into the body. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, 15 calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter. See, e.g., Wu et al., J. Biol. Chem. 267:963-7, 1992; Wu et al., J. Biol. Chem. 263:14621-4, 1988. Antisense methodology can be used to inhibit 20 zsig45 gene transcription, such as to inhibit cell proliferation in vivo. Polynucleotides that are complementary to a segment of a zsig45-encoding polynucleotide (e.g., a polynucleotide as set forth in SEQ ID NO:1) are designed to bind to zsig45-encoding mRNA and 25 to inhibit translation of such mRNA. Such antisense polynucleotides are used to inhibit expression of zsig45 polypeptide-encoding genes in cell culture or in a subject. Mice engineered to express the zsig45 gene, 30 referred to as "transgenic mice," and mice that exhibit a complete absence of zsig45 gene function, referred to as "knockout mice," may also be generated (Snouwaert et al., Science 257:1083, 1992; Lowell et al., Nature 366:740-42, 1993; Capecchi, M.R., Science 244: 1288-1292, 1989; WO99/28467 PCT/US98/25454 76 Palmiter, R.D. et al. Annu Rev Genet. 20: 465-499, 1986). For example, transgenic mice that over-express zsig45, either ubiquitously or under a tissue-specific or tissue restricted promoter can be used to ask whether over 5 expression causes a phenotype. For example, over expression of a wild-type zsig45 polypeptide, polypeptide fragment or a mutant thereof may alter normal cellular processes, resulting in a phenotype that identifies a tissue in which zsig45 expression is functionally relevant 10 and may indicate a therapeutic target for the zsig45, its agonists or antagonists. For example, a preferred transgenic mouse to engineer is one that over-expresses the mature zsig45 polypeptide. Moreover, such over expression may result in a phenotype that shows similarity 15 with human diseases. Similarly, knockout zsig45 mice can be used to determine where zsig45 is absolutely required in vivo. The phenotype of knockout mice is predictive of the in vivo effects of that a zsig45 antagonist, such as those described herein, may have. The human zsig45 cDNA 20 can be used to isolate murine zsig45 mRNA, cDNA and genomic DNA, which are subsequently used to generate knockout mice. These mice may be employed to study the zsig45 gene and the protein encoded thereby in an in vivo system, and can be used as in vivo models for 25 corresponding human diseases. Moreover, transgenic mice expression of zsig45 antisense polynucleotides or ribozymes directed against zsig45, described herein, can be used analogously to knockout mice described above. Other diagnostic applications using zsig45 can 30 be employed. For example, the zsig45 gene, a probe comprising zsig45 DNA or RNA or a subsequence thereof can be used to determine if the zsig45 gene is expressed differently in diseased tissues. For example, among other diseases, zsig45 may be expressed in certain pancreatic, WO99/28467 PCT/US98/25454 77 prostatic, intestinal, throat and lung cancers, or other diseases associated with those tissues. In the alternative, zsig45 expression in certain tissues may be decreased in certain disease states relative to normal. 5 With regard to modulating energy balance, zsig45 polypeptides may be used to modulate cellular metabolic reactions. Such metabolic reactions include adipogenesis, gluconeogenesis, glycogenolysis, lipogenesis, glucose uptake, protein synthesis, thermogenesis, oxygen 10 utilization and the like. The expression pattern of zsig45 polypeptide indicates expression in a major metabolic organ, thyroid, and may have intra- and extrathyroidal effects on endothelial cell tissues. Such effects involve protection, regeneration, growth and 15 development of thyroidal or other tissues. With regard to endothelial cell protection, zsig45 polypeptides may be used in organ preservation, for cryopreservation, for surgical pretreatment to prevent injury due to ischemia and/or inflammation or in like 20 procedures. In this regard, zsig45 polypeptides may find utility in modulating nutrient uptake, as demonstrated, for example, by 2-deoxy-glucose uptake in the brain or the like. The zsig45 polypeptides may modulate mammalian 25 energy balance. The thyroid expression pattern of zsig45 suggests that zsig45 may exhibit effects on glucose uptake, e.g. through GLUT-1, and thermogenesis (thermoregulation). Among other methods known in the art or described herein, mammalian energy balance may be 30 evaluated by monitoring one or more of the following metabolic functions: adipogenesis, gluconeogenesis, glycogenolysis, lipogenesis, glucose uptake, protein synthesis, thermogenesis, oxygen utilization or the like. These metabolic functions are monitored by techniques WO99/28467 PCT/US98/25454 78 (assays or animal models) known to one of ordinary skill in the art, as is more fully set forth below. For example, the glucoregulatory effects of insulin are predominantly exerted in the liver, skeletal muscle and 5 adipose tissue. Insulin binds to its cellular receptor in these three tissues and initiates tissue-specific actions that result in, for example, the inhibition of glucose production and the stimulation of glucose utilization. In the liver, insulin stimulates glucose uptake and inhibits 10 gluconeogenesis and glycogenolysis. In skeletal muscle and adipose tissue, insulin acts to stimulate the uptake, storage and utilization of glucose. Zsig45 polypeptide is expressed in thyroid but may exhibit extrathyroidal activity in organs that affect 15 metabolic functions. Thus, pharmaceutical compositions of the present invention may be useful in prevention or treatment of pancreatic disorders. For example, zsig45 may be associated with pathological regulation of the expansion of neurocrine and exocrine cells in the 20 pancreas, as evident in IDDM, pancreatic cancer or the like. Pharmaceutical compositions of the present invention may also be involved in prevention or treatment of pancreatic conditions characterized by dysfunction associated with pathological regulation of blood glucose 25 levels, insulin resistance or digestive function. Art-recognized methods exist for monitoring all of the metabolic functions recited above. Thus, one of ordinary skill in the art is able to evaluate zsig45 polypeptides, fragments, fusion proteins, antibodies, 30 agonists and antagonists for metabolic modulating functions. Exemplary modulating techniques are set forth below. Adipogenesis, gluconeogenesis and glycogenolysis are interrelated components of mammalian energy balance, WO99/28467 PCT/US98/25454 79 which may be evaluated by known techniques using, for example, ob/ob mice or db/db mice. The ob/ob mice are inbred mice that are homozygous for an inactivating mutation at the ob (obese) locus. Such ob/ob mice are 5 hyperphagic and hypometabolic, and are believed to be deficient in production of circulating OB protein. The db/db mice are inbred mice that are homozygous for an inactivating mutation at the db (diabetes) locus. The db/db mice display a phenotype similar to that of ob/ob 10 mice, except db/db mice display a more severe diabetic phenotype. Such db/db mice are believed to be resistant to the effects of circulating OB protein. Also, various in vitro methods of assessing these parameters are known in the art. 15 Insulin-stimulated lipogenesis, for example, may be monitored by measuring the incorporation of 14 C-acetate into triglyceride (Mackall et al. J. Biol. Chem. 251:6462 6464, 1976) or triglyceride accumulation (Kletzien et al., Mol. Pharmacol. 41:393-398, 1992). 20 Glucose uptake may be evaluated, for example, in an assay for insulin-stimulated glucose transport. Non transfected, differentiated L6 myotubes (maintained in the absence of G418) are placed in DMEM containing 1 g/l glucose, 0.5 or 1.0% BSA, 20 mM Hepes, and 2 mM glutamine. 25 After two to five hours of culture, the medium is replaced with fresh, glucose-free DMEM containing 0.5 or 1.0% BSA, 20 mM Hepes, 1 mM pyruvate, and 2 mM glutamine. Appropriate concentrations of insulin or IGF-1, or a dilution series of the test substance, are added, and the 30 cells are incubated for 20-30 minutes. 3 H or 1 4 C-labeled deoxyglucose is added to z50 1 M final concentration, and the cells are incubated for approximately 10-30 minutes. The cells are then quickly rinsed with cold buffer (e.g. PBS), then lysed with a suitable lysing agent (e.g. 1% SDS WO99/28467 PCT/US98/25454 80 or 1 N NaOH). The cell lysate is then evaluated by counting in a scintillation counter. Cell-associated radioactivity is taken as a measure of glucose transport after subtracting non-specific binding as determined by 5 incubating cells in the presence of cytochalasin b, an inhibitor of glucose transport. Other methods include those described by, for example, Manchester et al., Am. J. Physiol. 266 (Endocrinol. Metab. 29):E326-E333, 1994 (insulin-stimulated glucose transport). 10 Protein synthesis may be evaluated, for example, by comparing precipitation of 35 S-methionine-labeled proteins following incubation of the test cells with 35S methionine and 35 S-methionine and a putative modulator of protein synthesis. 15 Thermogenesis may be evaluated as described by B. Stanley in The Biology of Neuropeptide Y and Related Peptides, W. Colmers and C. Wahlestedt (eds.), Humana Press, Ottawa, 1993, pp. 457-509; C. Billington et al., Am. J. Physiol. 260:R321, 1991; N. Zarjevski et al., 20 Endocrinology 133:1753, 1993; C. Billington et al., Am. J. Physiol. 266:R1765, 1994; Heller et al., Am. J. Physiol. 252(4 Pt 2): R661-7, 1987; and Heller et al., Am. J. Physiol. 245(3): R321-8, 1983. Also, metabolic rate, which may be measured by a variety of techniques, is an 25 indirect measurement of thermogenesis. Oxygen utilization may be evaluated as described by Heller et al., Pflugers Arch 369(1): 55-9, 1977. This method also involved an analysis of hypothalmic temperature and metabolic heat production. Oxygen 30 utilization and thermoregulation have also been evaluated in humans as described by Haskell et al., J. Appl. Physiol. 51(4): 948-54, 1981. The zsig45 polypeptides of the present invention may act in the neuroendocrine/exocrine cell fate decision WO99/28467 PCT/US98/25454 81 pathway and is therefore capable of regulating the expansion of neuroendocrine and exocrine cells in the pancreas. One such regulatory use is that of islet cell regeneration. Also, it has been hypothesized that the 5 autoimmunity that triggers IDDM starts in utero, and zsig45 polypeptide is a developmental gene involved in cell partitioning. Assays and animal models are known in the art for monitoring the exocrine/neuroendocrine cell lineage decision, for observing pancreatic cell balance 10 and for evaluating zsig45 polypeptide, fragment, fusion protein, antibody, agonist or antagonist in the prevention or treatment of the conditions set forth above. Among other methods known in the art or 15 described herein, mammalian endothelial cell tissue protection may be evaluated by monitoring the function of endothelial tissue. For example, the function of the heart (aorta) may be evaluated by monitoring acetylcholine release, norepinephrine release or like parameters. These 20 parameters are monitored by techniques (assays or animal models) known to one of ordinary skill in the art, as is more fully set forth below. Acetylcholine and norepinephrine release may be monitored by HPLC. Levy, Electrophysiology of the 25 Sinoatrial and Atrioventricular Nodes, Alan R. Liss, Inc., 187-197, 1998, describes measurement of norepinephrine in coronary sinus effluent. In addition, animals may be electrically paced, with the results monitored as described by Elsner, European Heart Journal 16(Supplement 30 N) 52-8, 1995; and Reiffel and Kuehnert, PACE 17(Part 1): 349-65, 1994. The zsig45 polypeptide is also expressed in the colon. Thus, zsig45 polypeptide pharmaceutical compositions of the present invention may also be useful WO99/28467 PCTIUS98/25454 82 in prevention or treatment of digestive disorders in the GI tract, such as disorders associated with pathological secretory cell expansion or differentiation. Assays and animal models are known in the art for monitoring such 5 expansion or differentiation and for evaluating zsig45 polypeptides, including polypeptide fragments, fusion proteins, antibodies, agonists and antagonists in the prevention or treatment thereof. Moreover, trefoil factors in the intestine are 10 known to be involved in mucosal stabilization in the gut and repair processes associated with acute injury, particularly epithelial restitution (Poulsom, R., Bail. Clin. Gastro., 10: 113-134, 1996; Sands, B.E., and Podolsky, D.K., Annu. Rev. Physiol., 58: 253-273, 1996). 15 Also, trefoil proteins appear to have a role in healing wounds caused by intestinal inflammatory diseases, and resisting microbial invasion via mucosal secretion involvement (Palut, A.G., New Eng. J. Med., 336: 5-6-507, 1997; Playford, R.J., J. Royal Coll. Phys. London, 31: 37 20 41, 1997). Epidermal growth factor (EGF) receptor ligands may play a role in enhancing trefoil activity in the gut; however, repair of mucosal injury is not dependent on the main endogenous EGF receptor ligand in the gut, TNF-a, suggesting a role of other, undiscovered ligands (Cook, 25 G.A., et al., Am. Physiol. Soc., G1540-G1549, 1997). For example, the zsig45 polypeptides may serve as such ligand, regulatory protein or other factor in the trefoil pathway, and hence play an important therapeutic role in diseases and injury associated with the gut and mucosal epithelium. 30 EGF is also expressed in thyroid and modulates the growth and differentiation of thyroid cells in vitro (Dagogo-Jack, S., Afr. J. Med. Sci., 24:211-217, 1995). Thus, interaction of zsig45 with EGF receptor may also WO99/28467 PCTIUS98/25454 83 affect thyroid function and hence play a therapeutic role in thyroid diseases, or diseases associated with thyroid malfunction. Many growth factors are detected in thyroid tissue (Dagogo-Jack, S., ibid.); zsig45 may affect on one 5 or more of these other factors' activities or physiologic pathways. Thyroid expression of zsig45 suggests that the polypeptides of the present invention may be analogous to known thyroid hormones by acting upon cell membranes of 10 extrathyroidal tissues. Thus, the polypeptides of the present invention may exert non-nuclear effects on cell membranes and be useful in therapeutic applications in tissues such as heart and lymphoid tissues. For example, membrane effects may include inactivation of the 15 myocardial Na -channel or stimulation of red cell Ca2+ ATPase activity. Thus, zsig45 peptides of the present invention may be used in treatment of heart disease or malfunctions in myocardial contractility, or other diseases associated with solute transport and ion 20 channels, such as kidney, bone marrow, muscular, heart and or neural pathologies associated with genetic and other human disease states, such as diabetes, bone disease, hematopoietic disorders, immune disorders, leukemias, hypertension, cardiac hypertrophy, other cardiac disorders 25 and neural diseases. The effects of thyroid function on cardiac function are well documented (Lompre, A., et al., J. Mol. Cell Cardiol., 26:1109-1121, 1994). In animals, enhanced contraction and relaxation velocities are associated with 30 hyperthyroidism, and decreased contractility is associated with hypothyroidism. These effects may be mediated through the Ca2+-ATPase found in the myocardial sarcoplasmic reticulum. Such effects can readily be measured using assays disclosed below.
WO99/28467 PCTIUS98/25454 84 The cardiac activity of molecules of the present invention may be measured using a Langendorff assay. This preferred assay measures ex vivo cardiac function for an experimental animal, and is well known in the art. 5 Experimental animals are, for example but not limited to, rats, rabbits and guinea pigs. Chronic effects on heart tissue can be measured after treating a test animal with zsig45 polypeptide for 1 to 7 days, or longer. Control animals will have only received buffer. After treatment, 10 the heart is removed and perfused retrograde through the aorta. During perfusion, several physiologic parameters are measured: coronary blood flow per time, left ventricular (LV) pressures, and heart rate. These perameters directly reflect cardiac function. Changes in 15 these parameters, as measured by the Langendorff assay, following in vivo treatment with zsig45 polypeptide relative to control animals indicates a chronic effect of the polypeptide on heart function. Moreover, the Langendorff assay can also be employed to measure the 20 acute effects of zsig45 polypeptide on heart. In such application, hearts from untreated animals are used and zsig45 polypeptide is added to the perfusate in the assay. The parameters assessed above are measured and compared with the results from control hearts where zsig45 25 polypeptide was omitted from the perfusate. Differences in heart rate, change in pressure per time, and/or coronary blood flow indicate an acute effect of the molecules of the present invention on heart function. The activity of molecules of the present 30 invention may also be measured using a variety of assays that measure ion channel activity. Of particular interest is measuring ion transfer cross cell membranes. Such assays are well known in the art. Specific assays to assess the activity of novel ion channels or their WO99/28467 PCTIUS98/25454 85 regulators include, but are not limited to, bioassays measuring voltage-dependent conductance in Xenopus laevis oocytes (see, Rudy, B., Iverson, L.E., eds., Meth. Enzymol., vol. 207, Academic Press, San Diego, CA, 1992; 5 Hamill, O.P et al., Pfluegers Arch. 391:85-100, 1981; Moorman, J.R. et al., J. Biol. Chem. 267:14551-14554, 1992; Durieux, M.E., et al., Am. J. Physiol. 263:C896 C900, 1992). This method involves injecting in vitro expressed mRNAs into isolated oocytes and assessing 10 voltage-dependent conductance using a patch-clamp technique. An ion channel or its regulator may increase voltage-dependent conductance in this assay system. This system may be applied to other cell types, such as insect and mammalian cells (see, Rudy, B., Iverson, L.E., eds., 15 ibid.). Other assays involve measuring ion channel activity indirectly in mammalian or other cell types, through the use of a chelator dye, such as Fura2 (See, for example, James-Kracke M.R., J. Gen. Physiol. 99:41-62, 1992; Raghu, P. et al., Gene 190:151-156, 1997). Ion 20 channel activity can also be monitored by using a radiolabeled ion, such as a 125I efflux assay (Xia, Y. et al., J. Membr. Biol. 151:269-278, 1996). Other assays involve measuring changes in gene expression in mammalian cells signaled by ion flux or ion channel phosphorylation; 25 for example, by driving expression of a measurable reporter gene, e.g. luciferase, under a suitable promoter as disclosed herein. The molecules of the present invention may be useful for proliferation of cardiac tissue cells, such as 30 cardiac myocytes or myoblasts; skeletal myocytes or myoblasts and smooth muscle cells; chrondrocytes; endothelial cells; adipocytes and osteoblasts in vitro. For example, molecules of the present invention are useful as components of defined cell culture media, and may be WO99/28467 PCTUS98/25454 86 used alone or in combination with other cytokines and hormones to replace serum that is commonly used in cell culture. Molecules of the present invention are particularly useful in specifically promoting the growth 5 and/or development of myocytes in culture, and may also prove useful in the study of cardiac myocyte hyperplasia and regeneration. The polypeptides, nucleic acids and/or antibodies of the present invention may be used in 10 treatment of disorders associated with myocardial infarction, congestive heart failure, hypertrophic cardiomyopathy and dilated cardiomyopathy. Molecules of the present invention may also be useful for limiting infarct size following a heart attack, aiding in recovery 15 after heart transplantation, promoting angiogenesis and wound healing following angioplasty or endarterectomy, to develop coronary collateral circulation, for revascularization in the eye, for complications related to poor circulation such as diabetic foot ulcers, for stroke, 20 following coronary reperfusion using pharmacologic methods, and other indications where angiogenesis is of benefit. Molecules of the present invention may be useful for improving cardiac function, either by inducing cardiac myocyte neogenesis and/or hyperplasia, by inducing 25 coronary collateral development, or by inducing remodeling of necrotic myocardial area. Other therapeutic uses for the present invention include induction of skeletal muscle neogenesis and/or hyperplasia, kidney regeneration and/or for treatment of systemic and pulmonary hypertension. 30 zsig45 induced coronary collateral development is measured in rabbits, dogs or pigs using models of chronic coronary occlusion (Landau et al., Amer. Heart J. 29:924-931, 1995; Sellke et al., Surgery 120(2):182-188, 1996; and Lazarous et al., 1996, ibid.) Zsig45 efficacy WO99/28467 PCT/US98/25454 87 for treating stroke is tested in vivo, in rats, utilizing bilateral carotid artery occlusion and measuring histological changes, as well as maze performance (Gage et al., Neurobiol. Aging 9:645-655, 1988). Zsig45 efficacy 5 in hypertension is tested in vivo utilizing spontaneously hypertensive rats (SHR) for systemic hypertension (Marche et al., Clin. Exp. Pharmacol. Physiol. Suppl. 1:S114-116, 1995). 10 Polynucleotides of the present invention are also used to detect abnormalities on human chromosome 2 associated with disease or other human traits. The polynucleotides of the present invention map to the 2q37.3 region on human chromosome 2. The zsig45 gene maps 1086.2 15 cR 3000 from the top of the human chromosome 2 linkage group on the WICGR radiation hybrid map. Proximal and distal framework markers were WI-6310 (D2S2704) and D2S2585, respectively. The use of surrounding markers positions the zsig45 gene in the 2q37.3 region on the 20 integrated LDB chromosome 2 map. The present invention also provides reagents which will find use in diagnostic applications. For example, the zsig45 gene, a probe comprising zsig45 DNA or RNA, or a subsequence thereof, can be used to determine if 25 the zsig45 gene is present on chromosome 2 or if a mutation has occurred. Detectable chromosomal aberrations at the zsig45 gene locus include but are not limited to aneuploidy, gene copy number changes, insertions, deletions, restriction site changes, and rearrangements. 30 Such aberrations can be detected using polynucleotides of the present invention by employing molecular genetic techniques, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, and other genetic WO99/28467 PCTIUS98/25454 88 linkage analysis techniques known in the art (Sambrook et al., ibid.; Ausubel, et. al., ibid.; Marian, A.J., Chest, 108: 255-265, 1995). Zsig45 polynucleotide probes can be used to 5 detect abnormalities or genotypes associated with or located at 2q37.3, that manifest themselves in human disease states as well as map to this region of the human genome. See the Online Mendellian Inheritance of Man (OMIM) gene map, and references therein, for this region 10 of chromosome 2 on a publicly available WWW server (http://www3.ncbi.nlm.nih.gov/htbin post/Omim/getmap?chromosome=2q37.3) . All of these that manifest themselves in human disease states serve as possible candidate genes for an inheritable disease which 15 show linkage to the same chromosomal region as the zsig45 gene. Similarly, defects in the zsig45 locus itself may result in a heritable human disease state. Molecules of the present invention, such as the polypeptides, 20 antagonists, agonists, polynucleotides and antibodies of the present invention would aid in the detection, diagnosis prevention, and treatment associated with a zsig45 genetic defect. Other diagnostic applications using zsig45 can 25 be employed. For example, the zsig45 gene probe comprising zsig45 DNA or RNA, or a subsequence thereof, can be used to determine if the zsig45 gene is expressed differently in diseased tissues. Thus, such a zsig45 probe can be used to assess thyroid function. For 30 example, among other diseases, zsig45 may be expressed in certain thyroid, pituitary, colon, bone and endocrine cancers, or other diseases associated with those tissues. In the alternative, zsig45 expression in certain tissues may be decreased in certain disease states relative to 35 normal.
WO99/28467 PCTIUS98/25454 89 For pharmaceutical use, the polypeptides of the present invention are formulated for parenteral, particularly intravenous or subcutaneous, delivery 5 according to conventional methods. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. For applications for which local effects are preferred, such as for influencing the formation of certain types of mature cells 10 from localized (e.g., thyroid) stem cells, formulations designed for local administration are preferred. Such pharmaceutical compositions are amenable, for example, to implantation or other local delivery method and may additionally be formulated for sustained release. 15 Formulation of pharmaceutical compositions for a variety of modes of administration is within the level of ordinary skill in the art. In general, pharmaceutical formulations will include a zsig45 polypeptide in combination with a 20 pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. Methods of 25 formulation are well known in the art and are disclosed, for example, in Remington: The Science and Practice of Pharmacy, Gennaro, ed., Mack Publishing Co., Easton, PA, 19th ed., 1995. Therapeutic doses will generally be determined by the clinician according to accepted 30 standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art. The polypeptides may be administered for acute treatment, over one week or less, often over a WO99/28467 PCT/US98/25454 90 period of one to three days or may be used in chronic treatment, over several months or years. The invention is further illustrated by the 5 following non-limiting examples. EXAMPLES Example 1 10 Identification of zsig45 A. Using an EST Sequence to Obtain Full-length zsig45 Scanning of a translated in-house pituitary library DNA database using a signal trap as a query resulted in identification of an expressed sequence tag 15 (EST) sequence found to be homologous to a human secretory signal sequence. Oligonucleotide primers were designed from the sequence of the identified EST. The primers were used for priming internally within the EST to isolate a full-length clone from the human pituitary cDNA library. 20 B. Isolation of full length zsig45 cDNA: To obtain a full-length cDNA, 3' RACE was employed. A 3' RACE product was generated using a human pituitary cDNA library as template and oligonucleotides ZC 25 694 (SEQ ID NO:16) and ZC 14,030 (SEQ ID NO:17) as primers. This first-round 3' RACE PCR reaction was run as follows: 1 cycle at 94- for 5 minutes; 35 cycles at 940 ' for 30 seconds, then 55 30 seconds, then 72 for 3 minutes. 30 The resulting DNA products were electrophoresed on a 1.5% agarose gel, and a prominent band at approximately 650 bp was seen. The DNA band was gel purified and subcloned into a PCR-blunt T M vector (Invitrogen, San Diego, CA). Sequence analyses of the WO99/28467 PCTIUS98/25454 91 subclone revealed that the DNA products included the EST DNA sequence. This 650 bp insert was liberated from the vector by restriction enzyme digestion with EcoRI and was 5 electrophoresed on a 1% agarose gel. The fragment was purified using a commercially available gel extraction kit (QiaexlITM; Qiagen Inc., Chatsworth, CA), and then radioactively labeled with 32 P-dCTP using Prime-It II, a random prime labeling system (Stratagene Cloning Systems, 10 La Jolla, CA), according to the manufacturer's specifications. The probe was then purified using a Nuc Trap TM column (Stratagene) according to the manufacturer's instructions. ExpressHybTM (Clontech, Palo Alto, CA) solution was used for prehybridization and as a 15 hybridizing solution for colony lifts of the human pituitary library. Hybridization took place overnight at 65'C using 5 x 106 cpm/ml of labeled probe. The colony lifts were then washed in 2X SSC/1% SDS at 65 , followed by a wash in 0.1X SSC/0.1% SDS at 55 . Hybridizing clones 20 were isolated and discovered to contain a full-length cDNA encoding zsig45 protein. Example 2 Tissue Distribution 25 Northern blot analysis was performed using Human Multiple Tissue Blots (MTN I, MTN II, and MTN III) (Clontech). The vector containing the 650 bp cloned insert described in Example 1 was restriction enzyme digested and electrophoresed on a 1% agarose gel. The 650 30 bp fragment was purified using a commercially available kit (Qiaexl ITM; Qiagen) and then radioactively labeled with 32P-dCTP using Prime-It II, a random prime labeling system (Stratagene Cloning Systems), according to the manufacturer's specifications. The probe was then WO99/28467 PCT/US98/25454 92 purified using a Nuc-Trap T M column (Stratagene) according to the manufacturer's instructions. ExpressHyb
TM
(Clontech) solution was used for prehybridization and as a hybridizing solution for the Northern blots. 5 Hybridization took place overnight at 65 0 C using 5 x 106 cpm/ml of labeled probe. The blots were then washed in 2X SSC/1% SDS at 65 , followed by a wash in 0.1X SSC/0.1% SDS at 55 ,. One transcript size was detected at approximately 650 bp. Signal intensity was highest for 10 thyroid. No signals at 650 bp were present in any other tissues represented on the blots. Dot Blots were also performed using Human RNA Master BlotsTM (Clontech). The methods and conditions for the Dot Blots are the same as for the Multiple Tissue 15 Blots disclosed above. Strong signal intensity was present in thyroid gland, and pituitary gland. Less intense signals were indicated in colon. Example 3 20 PCR-Based Chromosomal Mapping of the zsig45 Gene Zsig45 was mapped to chromosome 2 using the commercially available "GeneBridge 4 Radiation Hybrid Panel" (Research Genetics, Inc., Huntsville, AL). The GeneBridge 4 Radiation Hybrid Panel contains DNAs from 25 each of 93 radiation hybrid clones, plus two control DNAs (the HFL donor and the A23 recipient). A publicly available WWW server (http://www-genome.wi.mit.edu/cgi bin/contig/rhmapper.pl) allows mapping relative to the Whitehead Institute/MIT Center for Genome Research's 30 radiation hybrid map of the human genome (the "WICGR" radiation hybrid map) which was constructed with the GeneBridge 4 Radiation Hybrid Panel.
WO99/28467 PCT/US98/25454 93 For the mapping of zsig45 with the "GeneBridge 4 RH Panel", 20 pl reactions were set up in a 96-well microtiter plate (Stratagene, La Jolla, CA) and used in a "RoboCycler Gradient 96" thermal cycler (Stratagene). Each 5 of the 95 PCR reactions consisted of 2 pl 10X KlenTaq PCR reaction buffer (Clontech), 1.6 pl dNTPs mix (2.5 mM each, Perkin-Elmer, Foster City, CA), 1 pl sense primer, ZC 15,414 (SEQ ID NO:18) 1 pl antisense primer, ZC 15,413 (SEQ ID NO:19), 2 pl "RediLoad" (Research Genetics, 10 Inc.), 0.4 pl 50X Advantage KlenTaq Polymerase Mix (Clontech), 25 ng of DNA from an individual hybrid clone or control and ddH 2 0 for a total volume of 20 pl. The reactions were overlaid with an equal amount of mineral oil and sealed. The PCR cycler conditions were as 15 follows: an initial 1 cycle 5 minute denaturation at 95 0 C 40 cycles of a 1 minute denaturation at 95 0 C, 1 minute annealing at 62oC and 1.5 minute extension at 72 0 C; followed by a final 1 cycle extension of 7 minutes at 72 0 C. The reactions were separated by electrophoresis on a 2% 20 agarose gel (Life Technologies, Gaithersburg, MD). The results showed that zsig45 maps 1086.2 cR_3000 from the top of the human chromosome 2 linkage group on the WICGR radiation hybrid map. Proximal and 25 distal framework markers were WI-6310 (D2S2704) and
D
2 S2585,respectively. The use of surrounding markers positions zsig45 in the 2q37.3 region on the integrated LDB chromosome 2 map (The Genetic Location Database, University of Southhampton, WWW server: 30 http://cedar.genetics. soton.ac.uk/public html/) Example 4 WO99/28467 PCT/US98/25454 94 Construction and expression of zsig45 Amino Terminal Glu Glu Tagged and Carboxy Terminal Glu-Glu Tagged Yeast Expression Vectors Expression of zsig45 in Pichia methanolica 5 utilizes the expression system described in co-assigned WIPO publication WO 97/17450. An expression plasmid containing all or part of a polynucleotide encoding zsig45 is constructed via homologous recombination. Expression vectors were built from pCZR204 to express a C-terminal 10 Glu-Glu-tagged (CEE), or an N-terminal Glu-Glu-tagged (NEE) zsig45 polypeptide. The pCZR204 vector contains the AUG1 promoter, followed by the xFpp leader sequence, followed by an N-terminal Glu-Glu tag, a blunt-ended Sma I restriction site, a carboxy-terminal peptide tag (Glu 15 Glu), a translational STOP codon, followed by the AUG1 terminator, the ADE2 selectable marker, and finally the AUG1 3' untranslated region. Also included in this vector are the URA3 and CEN-ARS sequences required for selection and replication in S. cerevisiae, and the AmpR and colEl 20 ori sequences required for selection and replication in E. coli. The zsig45 sequence inserted into these vectors begins at residue 47 (Lys) of the zsig45 amino acid sequence (SEQ ID NO:2). For each construct two linkers are prepared, and 25 along with zsig45, were homologously recombined into the yeast expression vectors described above. The untagged N terminal linker (SEQ ID NO:20) spans 70 base pairs of the alpha factor prepro (aFpp) coding sequence on one end and joins it to the 70 base pairs of the amino-terminus coding 30 sequence from the mature zsig45 sequence on the other. The NEE-tagged linker (SEQ ID NO:21) joins Glu-Glu tag (SEQ ID NO:22) between the aFpp coding sequence and the zsig45 sequence. The untagged C-terminal linker (SEQ ID NO:23) spans about 70 base pairs of carboxy terminus WO99/28467 PCT/US98/25454 95 coding sequence of the zsig45 on one end with 70 base pairs of AUG1 terminator sequence. The CEE-tagged linker (SEQ ID NO:24) inserts the Glu-Glu tag (SEQ ID NO:22) between the C-terminal end of zsig45 and the AUG1 5 terminator region. To make the NEE-tagged zsig45, the NEE-tagged linker and the untagged C-terminal linker were employed in the homologous recombination event.; to make the CEE-tagged zsig45, the untagged N-terminal linker and the CEE-tagged linker were employed in the homologous 10 recombination event. Construction of the NEE-tagged-zsig45 plasmid An NEE-tagged-zsig45 plasmid was made by homologously recombining 100 ng of the SmaI digested pCZR204 acceptor vector, 1 pg of Eco RI-BamHI zsig45 cDNA 15 donor fragment, 1 gg NEE-tagged-zsig45 linker (SEQ ID NO:21) and 1 gg of C-terminal untagged linker (SEQ ID NO:23) in S. cerevisiae (SF838-9D) (Rothman, J. et al., EMBO J. 8:2057-2065, 1989). The NEE-zsig45 linker was synthesized by a PCR 20 reaction. To a final reaction volume of 100 ml was added 1 pmol each of sense and antisense central oligos, ZC13,731 (SEQ ID NO:25) and ZC15,264 (SEQ ID NO:26) respectively; 100 pmol each of sense and antisense oligo primers, ZC13,497 (SEQ ID NO:27) and ZC15,272 (SEQ ID 25 NO:28) respectively; 10 il of 10X PCR buffer (Boehringer Mannheim), 1 jl Pwo Polymerase (Boehringer Mannheim), 10 jl of 0.25 mM nucleotide triphosphate mix (Perkin Elmer) and dH 2 0. The PCR reaction was run 10 cycles at 30 seconds at 94 0 C, 1 minute at 50oC and 1 minute at 72 0 C, concluded 30 with a 6 minute extension at 720. The resulting 338 bp double stranded, NEE-tagged linker is disclosed in SEQ ID NO:21.
WO99/28467 PCTIUS98/25454 96 The C-terminal untagged zsig45 linker was made via a PCR reaction as described using sense and antisense central oligos, ZC15,725 (SEQ ID NO:29) and ZC15,633 (SEQ ID NO:30) respectively; and sense and antisense oligo 5 primers, ZC15,271 (SEQ ID NO:31) and ZC13,734 (SEQ ID NO:32) respectively. The resulting 290 bp double stranded, C-terminal untagged linker is disclosed in SEQ ID NO:23. Construction of the CEE-zsig45 plasmid 10 A CEE-zsig45 plasmid was made by homologously recombining 100 ng of SmaI digested pCZR204 acceptor vector, the 1tg of EcoRI-BamHI zsig45 cDNA donor fragment, 1 gg of N-terminal untagged zsig45 linker (SEQ ID NO:20) and 1 gg of CEE-tagged linker (SEQ ID NO:24) in a S. 15 cerevisiae. The N-terminal untagged zsig45 linker was made via a PCR reaction as described above using sense and antisense central oligos, ZC15,14,821 (SEQ ID NO:33) and ZC15,265 (SEQ ID NO:34) respectively; and sense and 20 antisense oligo primers, ZC14,822 (SEQ ID NO:35) and ZC15,272 (SEQ ID NO:28) respectively. The resulting 244 bp double stranded, N-terminal untagged linker is disclosed in SEQ ID NO:20. The CEE-tagged linker was made via a PCR 25 reaction as described above using sense and antisense central oligos, ZC15,763 (SEQ ID NO:36) and ZC15,633 (SEQ ID NO:30) respectively; and sense and antisense oligo primers, ZC15,271 (SEQ ID NO:31) and ZC13,734 (SEQ ID NO:32) respectively. The resulting approximately 288 bp 30 double stranded, CEE-tagged linker is disclosed in SEQ ID NO:24. One hundred microliters of competent yeast cells (S. cerevisiae) was independently combined with 10 ml of the various DNA mixtures from above and transferred to a WO99/28467 PCTIUS98/25454 97 0.2 cm electroporation cuvette. The yeast/DNA mixtures were electropulsed at 0.75 kV (5 kV/cm), o ohms, 25 pF. To each cuvette was added 600 pl of 1.2 M sorbitol and the yeast was plated in two 300 pl aliquots onto two URA D 5 plates and incubated at 30 0 C. After about 48 hours the Ura + yeast transformants from a single plate were resuspended in 2.5 ml H20 and spun briefly to pellet the yeast cells. The cell pellet was resuspended in 1 ml of lysis buffer (2% 10 Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture was added to an Eppendorf tube containing 300 pl acid washed glass beads and 200 pl phenol-chloroform, vortexed for 1 minute intervals two or three times, followed by a 5 15 minute spin in a Eppendorf centrifuge as maximum speed. Three hundred microliters of the aqueous phase was transferred to a fresh tube and the DNA precipitated with 600 pl ethanol (EtOH), followed by centrifugation for 10 minutes at 4 0 C. The DNA pellet was resuspended in 100 pl 20 H20. Transformation of electrocompetent E. coli cells (MC1061; Casadaban, M. and S. Cohen, J. Mol. Biol. 138:179-207, 1980) was done with 1 tl yeast DNA prep and 50 gil of MC1061 cells. The cells were electropulsed at 25 2.0 kV, 25 JF and 400 ohms. Following electroporation, 1 ml SOC (2% BactoTM Tryptone (Difco, Detroit, MI), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl 2 , 10 mM MgSO 4 , 20 mM glucose) was plated in 250 pl aliquots on four LB AMP plates (LB broth (Lennox), 1.8% BactoTM Agar 30 (Difco), 100 mg/L Ampicillin). Individual clones harboring the correct expression construct for NEE and CEE tagged zsig45 constructs were identified by PCR and restriction digest, WO99/28467 PCT/US98/25454 98 and sequence analysis was used to verify the presence of the zsig45 insert and to confirm that the various DNA sequences had been joined correctly to one another. Larger scale plasmid DNA was isolated using the Qiagen 5 Maxi kit (Qiagen) according to manufacturer's instruction and the DNA was digested with NotI to liberate the Pichia zsig45 expression cassette from the vector backbone. The NotI-restriction digested DNA fragment was then transformed into the Pichia methanolica expression host, 10 PMAD16. This was done by mixing 100 l of prepared competent PMAD16 cells with 10 g of NotI restriction digested zsig45 and transferred to a 0.2 cm electroporation cuvette. The yeast/DNA mixture was electropulsed at 0.75 kV, 25 mF, infinite ohms. To the 15 cuvette was added 1 ml of 1.2 M sorbitol and 500 pl aliquots were plated onto two ADE DS (0.056% -Ade -Trp Thr powder, 0.67% yeast nitrogen base without amino acids, 2% D-glucose, 0.5% 200X tryptophan, threonine solution, and 18.22% D-sorbitol) plates for selection and incubated 20 at 30 0 C. Clones were picked and screened via Western blot for high-level zsig45 expression. The resulting NEE tagged-zsig45 plasmid containing yeast cells were designated PMAD16::pCZR207, and the CEE-tagged-zsig45 plasmid containing yeast cells were designated 25 PMAD16::pCZR210. The clones were then subjected to fermentation. Fermentation of P. methanolica PMAD16:pCZR207 for the expression of ZSIG45NEE was carried out in a 6.0 liter fed batch fermentation. The fermentation was 30 started in 3.0 liters of basal medium plus glucose. The tank was inoculated from a 20 hour old shake flask grown in YEPD at 300 C (8.0% v/v). Glucose dosing started at 12 hours into the run and ran at varied rates for the WO99/28467 PCT/US98/25454 99 remainder of the fermentation. Induction of the AUG1 promoter driving expression of the ZSIG45NEE protein was turned on by the initiation of methanol dosing at 40 hours elapsed fermentation time (EFT). The fermentation ran for 5 72 hours and was harvested by centrifugation. From 5.5 liters of fermentation broth approximately 3.0 liters of cell broth was obtained after cell removal. A non glycosylated protein was detected on western blots after probing with monoclonal antibody to the N terminal glu-glu 10 tag. Fermentation of P. methanolica PMAD16:pCZR210.1 for the expression of ZSIG45CEE was carried out as per above. A non-glycosylated protein was detected on western blots after probing with monoclonal antibody to the C 15 terminal glu:glu tag. Example 5 Purification of zsig45CEE and zsig45NEE polypeptide from Pichia methanolica infected cells 20 Unless otherwise noted, all operations were carried out at 4 0 C. The following procedure was used for purifying zsig45 polypeptide containing C-terminal or N terminal GluGlu (EE) tags. A Protease inhibitor solution was added to 3000 ml of conditioned media from Pichia 25 cultures (see, Example 4) to final concentrations of 2.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma Chemical Co. St. Louis, MO), 0.001 mM leupeptin (Boehringer Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer 30 Mannheim). The sample was centrifuged at 10,000 rpm for 30 min. at 4 0 C in a Beckman JLA-10.5 rotor (Beckman Instruments, Palo Alto, CA) in a Beckman Avanti J25I centrifuge (Beckman Instruments) to remove cell debris. To the supernatant fraction, 50.0 ml of anti-EE Sepharose WO99/28467 PCT/US98/25454 100 (prepared as described below) was added, and the mixture was gently agitated on a Wheaton (Millville, NJ) roller culture apparatus for 18.0 h at 40C. The mixture was poured into a 5.0 x 20.0 cm 5 Econo-Column (Bio-Rad, Laboratories, Hercules, CA) and the anti-EE Sepharose gel was washed with 30 column volumes of phosphate buffered saline (PBS). The absorbance at 280 nM of the unretained flow-through fraction was measured until the absorbance was less than 0.05. The flow-through 10 fraction was discarded. Once the absorbance of the flow through was less than 0.05, column flow rate was reduced to zero. The anti-EE Sepharose gel was then washed with 2.0 column volumes of PBS containing 0.2 mg/ml EE peptide (Anaspec, San Jose, CA) for 1.0 h at 4 0 C. The EE peptide 15 used has the sequence N-GluTyrMetProValAsp-C (SEQ ID NO:37). After washing, the column flow was resumed and the eluted polypeptide, containing both zsig45CEE (or zsig45NEE) polypeptide and EE peptide, was collected. This fraction is referred to as the "polypeptide elution 20 fraction." The anti-EE Sepharose gel was washed with 2.0 column volumes of 0.1M glycine, pH 2.5, and the glycine wash was collected separately. The pH of the glycine eluted fraction was adjusted to 7.0 by the addition of a small volume of 10X PBS and stored at 4 0 C for future 25 analysis if needed. The polypeptide elution fraction was concentrated to 5.0 ml using a 3,000 molecular weight cutoff membrane concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions. To separate 30 zsig45CEE or zsig45NEE polypeptide from free EE peptide, the concentrated polypeptide elution fraction was subjected to chromatography on a 1.5 x 50 cm Sephadex G-50 (Pharmacia, Piscataway, NJ) column equilibrated in PBS at a flow rate of 1.0 ml/min using a BioCad Sprint HPLC WO99/28467 PCT/US98/25454 101 (PerSeptive BioSystems, Framingham, MA). Two-ml fractions were collected and the absorbance at 280 nM was monitored. The first peak of material absorbing at 280 nM and eluting near the void volume of the column was collected. This 5 material represented purified zsig45CEE or zsig45NEE polypeptide and was further characterized by SDS-PAGE and Western blotting with anti-EE antibodies. On Coomassie Blue-stained SDS-PAGE gels, the zsig45 NEE preparation contained one major band of 10 apparent molecular weight 8000. The mobility of this band was the same in the presence and absence of reducing agents and was visible on western blots with anti-EE antibodies. The zsig45 CEE purified protein also showed one major band at 8000 Da on Coomassie-Blue stained SDS 15 PAGE gels. Western blotting with anti-EE antibodies showed one major band of cross-reactive material at 8000 Da and a minor component at 18,000 Da. The mobility of the 8000 Da band on SDS-PAGE gels or western blots was not changed by the presence or absence of reducing agents. 20 The protein concentration of the purified proteins was performed by BCA analysis (Pierce, Rockford, IL) and the material was aliquoted, and stored at -800C according to our standard procedures. The concentrations of purified zsig45NEE polypeptide was 0.35 mg/ml and 25 zsig45CEE polypeptide was 0.17 mg/ml. To prepare anti-EE Sepharose, a 100 ml bed volume of protein G-Sepharose (Pharmacia, Piscataway, NJ) was washed 3 times with 100 ml of PBS containing 0.02% sodium azide using a 500 ml Nalgene 0.45 micron filter 30 unit. The gel was washed with 6.0 volumes of 200 mM triethanolamine, pH 8.2 (TEA, Sigma, St. Louis, MO), and an equal volume of EE antibody solution containing 900 mg of antibody was added. After an overnight incubation at 4oC, unbound antibody was removed by washing the resin with WO99/28467 PCTIUS98/25454 102 5 volumes of 200 mM TEA as described above. The resin was resuspended in 2 volumes of TEA, transferred to a suitable container, and dimethylpimilimidate-2HCl (Pierce, Rockford, IL) dissolved in TEA, was added to a final 5 concentration of 36 mg/ml of protein G-Sepharose gel. The gel was rocked at room temperature for 45 min and the liquid was removed using the filter unit as described above. Nonspecific sites on the gel were then blocked by incubating for 10 min. at room temperature with 5 volumes 10 of 20 mM ethanolamine in 200 mM TEA. The gel was then washed with 5 volumes of PBS containing 0.02% sodium azide and stored in this solution at 4oC. Example 6 15 Generation of untagged zsig45 Recombinant Adenovirus The protein coding region of zsig45 was amplified by PCR using primers that added FseI and AscI restriction sties at the 5' and 3' termini respectively. PCR primers ZC17536 (SEQ ID NO:38) and ZC17537 (SEQ ID 20 NO:39) were used with template BluescriptSKIITM (Stratagene) plasmid containing the full-length zsig45 cDNA (Example 1) in a PCR reaction as follows: one cycle at 95 0 C for 5 minutes; followed by 15 cycles at 95 0 C for 1 min., 58 0 C for 1 min., and 72 0 C for 1.5 min.; followed by 25 72 0 C for 7 min.; followed by a 4 0 C soak. The PCR reaction product was loaded onto a 1.2 % (low melt) SeaPlaque GTG (FMC, Rockland, ME) gel in TAE buffer. The zsig45 PCR product was excised from the gel and purified using the QIAquick T M PCR Purification Kit gel cleanup kit as per kit 30 instructions (Qiagen). The PCR product was then digested with FseI-AscI, phenol/chloroform extracted, EtOH precipitated, and rehydrated in 20ml TE (Tris/EDTA pH 8). The 344 bp zsig45 fragment was then ligated into the FseI- WO 99/28467 PCT/US98/25454 103 AscI sites of the transgenic vector pTG12-8 (See, example 7) and transformed into DH10B competent cells by electroporation. Clones containing zsig45 were identified by plasmid DNA miniprep followed by digestion with Fsel 5 AscI. A positive clone was sent to the sequencing department to insure there are no deletions or other anomalies in the construct. The sequence of zsig45 cDNA was confirmed. Qiagen Maxi Prep protocol (Qiagen) is used to generate DNA to continue our process described below. 10 Preparation of DNA construct for generation of Adenovirus The 344 bp zsig45 cDNA was released from the TG12-8 vector using FseI and AscI enzymes. The cDNA was isolated on a 1% low melt SeaPlaque GTGTM (FMC, Rockland, ME) gel and was then excised from the gel and the gel 15 slice melted at 70 0 C, extracted twice with an equal volume of Tris buffered phenol, and EtOH precipitated. The DNA was resuspended in 10[l H 2 0. The zsig45 cDNA was cloned into the FseI-AscI sites of pAdTrack CMV (He, T-C. et al., PNAS 95:2509-2514, 20 1998) in which the native polylinker was replaced with FseI, EcoRV, and AscI sites. Ligation was performed using the Fast-LinkTM DNA ligation and screening kit (Epicentre Technologies, Madison, WI). In order to linearize the plasmid, approximately 5 tg of the pAdTrack CMV zsig45 25 plasmid was digested with PmeI. Approximately 1 tg of the linearized plasmid was cotransformed with 200ng of supercoiled pAdEasy (He et al., supra.) into BJ5183 cells. The co-transformation was done using a Bio-Rad Gene Pulser at 2.5kV, 200 ohms and 25mFa. The entire co 30 transformation was plated on 4 LB plates containing 25 [tg/ml kanamycin. The smallest colonies were picked and expanded in LB/kanamycin and recombinant adenovirus DNA identified by standard DNA miniprep procedures. Digestion WO 99/28467 PCT/US98/25454 104 of the recombinant adenovirus DNA with FseI-AscI confirmed the presence of zsig45. The recombinant adenovirus miniprep DNA was transformed into DH10B competent cells and DNA prepared using a Qiagen maxi prep kit as per kit 5 instructions. Transfection of 293a Cells with Recombinant DNA Approximately 5 tg of recombinant adenoviral DNA was digested with PacI enzyme (New England Biolabs) for 3 hours at 37 0 C in a reaction volume of 100 [il containing 20 10 30U of PacI. The digested DNA was extracted twice with an equal volume of phenol/chloroform and precipitated with ethanol. The DNA pellet was resuspended in 10 l distilled water. A T25 flask of QBI-293A cells (Quantum Biotechnologies, Inc. Montreal, Qc. Canada), inoculated 15 the day before and grown to 60-70% confluence, were transfected with the PacI digested DNA. The PacI-digested DNA was diluted up to a total volume of 50il with sterile HBS (150mM NaCl, 20mM HEPES). In a separate tube, 20 p4l DOTAP (Boehringer Mannheim, lmg/ml) was diluted to a total 20 volume of 100pl with HBS. The DNA was added to the DOTAP, mixed gently by pipeting up and down, and left at room temperature for 15 minutes. The media was removed from the 293A cells and washed with 5 ml serum-free MEMalpha (Gibco BRL) containing 1mM Sodium Pyruvate (GibcoBRL), 0.1 25 mM MEM non-essential amino acids (GibcoBRL) and 25mM HEPES buffer (GibcoBRL). 5 ml of serum-free MEM was added to the 293A cells and held at 37 0 C. The DNA/lipid mixture was added drop-wise to the T25 flask of 293A cells, mixed gently and incubated at 37 0 C for 4 hours. After 4 h the 30 media containing the DNA/lipid mixture was aspirated off and replaced with 5 ml complete MEM containing 5% fetal bovine serum. The transfected cells were monitored for WO99/28467 PCT/US98/25454 105 Green Fluorescent Protein (GFP) expression and formation of foci, i.e., viral plaques. Seven days after transfection of 293A cells with the recombinant adenoviral DNA, the cells expressed the 5 GFP protein and started to form foci. These foci are viral "plaques" and the crude viral lysate was collected by using a cell scraper to collect all of the 293A cells. The lysate was transferred to a 50ml conical tube. To release most of the virus particles from the cells, three 10 freeze/thaw cycles were done in a dry ice/ethanol bath and a 370 waterbath. Amplification of Recombinant Adenovirus (rAdV) The crude lysate was amplified (Primary (10) amplification) to obtain a working "stock" of zsig45 rAdV 15 lysate. Ten 10cm plates of nearly confluent (80-90%) 293A cells were set up 20 hours previously, 200ml of crude rAdV lysate added to each 10cm plate and monitored for 48 to 72 hours looking for CPE under the white light microscope and expression of GFP under the fluorescent microscope. When 20 all of the 293A cells showed CPE (Cytopathic Effect) this 10 stock lysate was collected and freeze/thaw cycles performed as described under Crude rAdV Lysate. Secondary (20) Amplification of zsig45 rAdV was obtained as follows: Twenty 15cm tissue culture dishes of 25 293A cells were prepared so that the cells were 80-90% confluent. All but 20 mls of 5%MEM media was removed and each dish was inoculated with 300-500ml 10 amplified rAdv lysate. After 48 hours the 293A cells were lysed from virus production and this lysate was collected into 250 ml 30 polypropylene centrifuge bottles and the rAdV purified. AdV/cDNA Purification NP-40 detergent was added to a final concentration of 0.5% to the bottles of crude lysate in order to lyse all cells. Bottles were placed on a WO99/28467 PCTIUS98/25454 106 rotating platform for 10 min. agitating as fast as possible without the bottles falling over. The debris was pelleted by centrifugation at 20,000 X G for 15 minutes. The supernatant was transferred to 250 ml polycarbonate 5 centrifuge bottles and 0.5 volumes of 20%PEG8000/2.5M NaCl solution added. The bottles were shaken overnight on ice. The bottles were centrifuged at 20,000 X G for 15 minutes and supernatant discarded into a bleach solution. The white precipitate in two vertical lines along the wall of 10 the bottle on either side of the spin mark is the precipitated virus/PEG. Using a sterile cell scraper, the precipitate from 2 bottles was resuspended in 2.5 ml PBS. The virus solution was placed in 2 ml microcentrifuge tubes and centrifuged at 14,000 X G in the microfuge for 15 10 minutes to remove any additional cell debris. The supernatant from the 2ml microcentrifuge tubes was transferred into a 15ml polypropylene snapcap tube and adjusted to a density of 1.34g/ml with cesium chloride (CsCl). The volume of the virus solution was estimated and 20 0.55 g/ml of CsCl added. The CsCl was dissolved and 1 ml of this solution weighed 1.34 g. The solution was transferred polycarbonate thick-walled centrifuge tubes 3.2ml (Beckman No. 362305) and spin at 80,000rpm (348,000 X G) for 3-4 hours at 250C in a Beckman Optima TLX 25 microultracentrifuge with the TLA-100.4 rotor. The virus formed a white band. Using wide-bore pipette tips, the virus band was collected. The virus from the gradient has a large amount of CsCl which must be removed before it can be used on 30 cells. Pharmacia PD-10 columns prepacked with Sephadex G 25M (Pharmacia) were used to desalt the virus preparation. The column was equilibrated with 20 ml of PBS. The virus was loaded and allow it to run into the column. 5 ml of PBS was added to the column and fractions of 8-10 drops WO 99/28467 PCT/US98/25454 107 collected. The optical densities of 1:50 dilutions of each fraction was determined at 260 nm on a spectrophotometer. A clear absorbance peak was present between fractions 7-12. These fractions were pooled and 5 the optical density (OD) of a 1:50 dilution determined. A formula is used to convert OD into virus concentration: (OD at 260nm)(50)(1.1 x 1012 ) = virions/ml. The OD of a 1:50 dilution of the zsig45 rAdV was 0.057, giving a virus concentration of 3.1 X 1012 virions/ml. 10 To store the virus, glycerol was added to the purified virus to a final concentration of 15%, mixed gently but effectively, and stored in aliquots at -800C. Tissue Culture Infectious Dose at 50% CPE (TCID 50) Viral Titration Assay 15 A protocol developed by Quantum Biotechnologies, Inc. (Montreal, Qc. Canada) was followed to measure recombinant virus infectivity. Briefly, two 96-well tissue culture plates were seeded with 1X10 4 293A cells per well in MEM containing 2% fetal bovine serum for each 20 recombinant virus to be assayed. After 24 hours 10-fold dilutions of each virus from 1X10 -2 to 1X10 -14 were made in MEM containing 2% fetal bovine serum. 100 l of each dilution was placed in each of 20 wells. After 5 days at 37 0 C, wells were read either positive or negative for 25 Cytopathic Effect (CPE) and a value for "Plaque Forming Units/ml" (PFU) is calculated.
TCID
50 formulation used was as per Quantum Biotechnologies, Inc., above. The titer (T) is determined from a plate where virus used is diluted from 10-2 to 10-14, 30 and read 5 days after the infection. At each dilution a ratio (R) of positive wells for CPE per the total number of wells is determined. To Calculate titer of the undiluted virus sample: the factor, "F" = 1+d(S-0.5); where "S" is the sum WO99/28467 PCT/US98/25454 108 of the ratios (R); and "d" is Logl0 of the dilution series, for example, "d" is equal to 1 for a ten-fold dilution series. The titer of the undiluted sample is T = 1 0 (1+') = TCIDso/ml. To convert TCIDs 5 o/ml to pfu/ml, 0.7 is 5 subtracted from the exponent in the calculation for titer (T). The zsig45 adenovirus had a titer of 1.1 X 1010 pfu/ml. 10 Example 7 Zsig45 Transgenic Mice Oligonucleotides were designed to generate a PCR fragment containing a consensus Kozak sequence and the exact zsig45 coding region. These oligonucleotides were 15 designed with an FseI site at the 5' end and an AscI site at the 3' end to facilitate cloning into pMT12-8, our standard transgenic vector. PMT12-8 contains the mouse MT-1 promoter and a 5' rat insulin II intron upstream of the FseI site. 20 PCR reactions were carried out with 200 ng human zsig45 template and oligonucleotides ZC17,536 (SEQ ID NO:38) and ZC17,537 (SEQ ID NO:39). PCR reaction conditions were as follows: 950C for 5 minutes; 15 cycles of 95 0 C for 60 seconds, 620C for 60 seconds, and 720C for 25 90 seconds; and 72 0 C for 7 minutes. PCR products were separated by agarose gel electrophoresis and purified using a QiaQuickTM (Qiagen) gel extraction kit. The isolated, 344 bp, DNA fragment was digested with FseI and AscI (Boerhinger-Mannheim), ethanol precipitated and 30 ligated into pMT12-8 that was previously digested with FseI and AscI. The pMT12-8 plasmid, designed for expression of a gene of interest in transgenic mice, contains an expression cassette flanked by 10 kb of MT-1 5' DNA and 7 kb of MT-1 3' DNA. The expression cassette WO99/28467 PCT/US98/25454 109 comprises the MT-1 promoter, the rat insulin II intron, a polylinker for the insertion of the desired clone, and the human growth hormone poly A sequence. About one microliter of the ligation reaction 5 was electroporated into DH10B ElectroMaxTM competent cells (GIBCO BRL, Gaithersburg, MD) according to manufacturer's direction and plated onto LB plates containing 100 g/ml ampicillin, and incubated overnight. Colonies were picked and grown in LB media containing 100 pg/ml ampicillin. 10 Miniprep DNA was prepared from the picked clones and screened for the zsig45 insert by restriction digestion with EcoRI, and subsequent agarose gel electrophoresis. Maxipreps of the correct pMT-zsig45 construct were performed. A SalI fragment containing with 5' and 3' 15 flanking sequences, the MT-1 promoter, the rat insulin II intron, zsig45 cDNA and the human growth hormone poly A sequence was prepared and used for microinjection into fertilized murine oocytes. Fifteen transgenic mice were identified among 54 20 pups. Liver biopsies were performed on all 15 transgenics and the liver zsig45 transgene mRNA was quantified by RT PCR. The exression profile was as follows: 3 high expressers (approximately 2400-5100 mRNA molecules/liver cell); 3 medium expressers (approximately 1600-1900 mRNA 25 molecules/liver cell); 4 low expressers (approximately 200-400 mRNA molecules/liver cell); and 5 having no detectable transgene expression. Example 8 30 zsig45 activity in vivo Potential activity of the zsig45 protein was tested in normal mice by daily subcutaneous injection of the purified protein preparation over a 14 day period. The experiment used 34 male mice of the C57BL6 strain WO99/28467 PCT/US98/25454 110 (Harlan Sprague Dawley, Indianapolis, IN) which were 8 weeks of age at the beginning of the study. The mice were divided into 4 groups: 10 mice received injections containing 10 micrograms of purified zsig45NEE polypeptide 5 (See, Example 5) contained in 0.1 ml of phosphate buffered saline (PBS) with 0.1% Bovine serum albumin (BSA) (ICN Pharmaceuticals); 10 mice received injections containing 10 micrograms of purified zsig45CEE polypeptide (See, Example 5) contained in 0.1 ml of PBS with 0.1% BSA; 9 10 mice received injections of the vehicle only (PBS containing 0.1% BSA; and 5 mice received no injection. The mice were weighed on day 0, 7, and 14. The mice were bled on day 7 and 14 for complete blood cell counts and to assess the mouse clinical chemistry panels using a mouse 15 chemistry screen from Everett Central Laboratory, Everett WA. On day 14 the mice were sacrificed and tissues were collected into formalin for histological analysis (see below). The blood chemistry panels were completely 20 normal and showed no significant differences between the groups of mice. Weight gain was not significnatly different between groups. Likewise, blood counts were all within normal range with no significant differences between groups. 25 Microscopic evaluation of skin: Skin samples (as well as other tissues) were isolated and prepared for histologic examination from animals subcutaneously administered zsig45CEE, zsig45-NEE or vehicle, bovine serum albumen (BSA) control. The skin 30 was harvested approximately 2 weeks after initiation of the experimental treatment. Samples were fixed in 10% buffered formalin, embedded in paraffin, sectioned at 3 microns, and stained with hematoxylin and eosin. The slides were examined and scored as to severity of WO99/28467 PCT/US98/25454 111 inflammation (0=none, l=mild, 2=moderate, 3=severe) by a board certified veterinary pathologist blinded to treatment. The mean severity scores of each treatment group were determined and analyzed with a GraphPad InStata 5 software package (GraphPad Software, San Diego, CA). The difference between the mean severity score of the zsig45 NEE group was significantly different than the animals given vehicle alone (p<0.05) by the Kruskal-Wallis test. The mean severity score of the zsig45-CEE (mean=2.1) group 10 was similar to the zsig45-NEE group (mean=2.3) but was not significantly different than the controls (mean=1.2). The skin slides were then randomly assorted, read by a boarded pathologist blinded to treatment, and ranked according to severity of inflammation from lowest 15 to highest. With the exception of one control mouse (which may have inadvertently been mislabeled at necropsy), the controls were all in the lowest half of the severity rankings. The inflammation primarily occurred in the subcutis at the injection site. Less 20 commonly, inflammatory foci were observed in the overlying deep dermis and underlying musculature. The inflammatory cells at the site consisted of lymphocytes, plasma cells, and macrophages with a smaller number of neutrophils, suggestive of chronic-active inflammation. There was also 25 a mild to moderate increase in fibrous connective tissue at the site of injection. The inflammation and fibrosis observed in the treatment groups was greater than that observed in the control animals, and the inflammation observed in conjunction with zsig45-NEE was slightly 30 greater than that observed with zsig45-CEE. The main difference between the BSA and zsig45 treated groups was in the severity and extent of the inflammation and fibrosis, being generally none to mild in the control (BSA WO99/28467 PCT/US98/25454 112 treated) groups and moderate to severe in the zsig45 treated groups. From the foregoing, it will be appreciated that, 5 although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
Claims (21)
1. An isolated polynucleotide that encodes a polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of: (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2; (b) the amino acid sequence as shown in SEQ ID NO:4 from amino acid number 1 (Met) to amino acid number 85 (Asp); (c) the amino acid sequence as shown in SEQ ID NO:3 from amino acid number 1 (Met) to amino acid number 89 (Asp); (d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid residue number 1 (Met) to amino acid residue number 114 (Asp).
2. An isolated polynucleotide molecule selected from the group consisting of: (a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:1 from nucleotide 219 to nucleotide 422; (b) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:1 from nucleotide 168 to nucleotide 422; (c) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:1 from nucleotide 156 to nucleotide 422; (d) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:l from nucleotide 82 to nucleotide 422; and (e) polynucleotide molecules complementary to (a), (b), (c), or (d). WO99/28467 PCT/US98/25454 114
3. An isolated polynucleotide sequence according to claim 1, wherein the polynucleotide comprises nucleotide 1 to nucleotide 342 of SEQ ID NO:15.
4. An isolated polynucleotide according to claim 1, wherein the polypeptide consists of a sequence of amino acid residues that is at least 90% identical the amino .acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2.
5. An isolated polynucleotide according to claim 1, wherein the polypeptide consists of a sequence of amino acid residues that is as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2.
6. An isolated polynucleotide according to claim 1, wherein the polypeptide contains motifs 1 through 5.
7. An expression vector comprising the following operably linked elements: a transcription promoter; a DNA segment encoding a zsig45 polypeptide that is 90% identical to and amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2; and a transcription terminator.
8. An expression vector according to claim 7, further comprising a secretory signal sequence operably linked to the DNA segment.
9. An expression vector according to claim 8, wherein the secretory signal sequence encodes and amino acid sequence selected from the group consisting of: WO99/28467 PCTIUS98/25454 115 (a) amino acids 1 through 46 of SEQ ID NO:2; (b) amino acids 1 through 21 of SEQ ID NO:3; and (c) amino acids 1 through 17 of SEQ ID NO:4.
10. A cultured cell into which has been introduced an expression vector according to claim 7, wherein the cell expresses a polypeptide encoded by the DNA segment.
11. A DNA construct encoding a fusion protein, the DNA construct comprising: a first DNA segment encoding a polypeptide that is at least 90% identical to a sequence of amino acids selected from the group consisting of: (a) amino acids 1 through 46 of SEQ ID NO:2; (b) amino acids 1 through 21 of SEQ ID NO:3; and (c) amino acids 1 through 17 of SEQ ID NO:4;and a second DNA segment encoding an additional polypeptide, wherein the first and second DNA segments are connected in-frame; and encode the fusion protein.
12. An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of: (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2; (b) the amino acid sequence as shown in SEQ ID NO:4 from amino acid number 1 (Met) to amino acid number 85 (Asp); (c) the amino acid sequence as shown in SEQ ID NO:3 from amino acid number 1 (Met) to amino acid number 89 (Asp); WO99/28467 PCT/US98/25454 116 (d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid residue number 1 (Met) to amino acid residue number 114 (Asp).
13. An isolated polypeptide according to claim 12, wherein the polypeptide consists of a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp).
14. An isolated polypeptide according to claim 12, wherein the sequence of amino acid residues is as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp).
15. An isolated polypeptide according to claim 12, wherein the sequence of amino acid residues contains motifs 1 through 5.
16. A method of producing a zsig45 polypeptide comprising: culturing a cell into which has been introduced an expression vector according to claim 7; and isolating the zsig45 polypeptide produced by the cell.
17. A method of producing an antibody to zsig45 polypeptide comprising: inoculating an animal with a polypeptide selected from the group consisting of: (a) a polypeptide consisting of 9 to 67 amino acids, wherein the polypeptide is at least 90% identical to a contiguous sequence of amino acids in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp); and WO99/28467 PCT/US98/25454 117 (b) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp); and wherein the polypeptide elicits an immune response in the animal to produce the antibody; and isolating the antibody from the animal.
18. An antibody produced by the method of claim 17, which binds to a zsig45 polypeptide.
19. The antibody of claim 18, wherein the antibody is a monoclonal antibody.
20. An antibody which binds to a polypeptide of claim 12.
21. A method of detecting, in a test sample, the presence of an antagonist of zsig45 protein activity, comprising: transfecting a zsig45-responsive cell, with a reporter gene construct that is responsive to a zsig45 stimulated cellular pathway; and producing a zsig45 polypeptide by the method of claim 16; and adding the zsig45 polypeptide to the cell, in the presence and absence of a test sample; and comparing levels of response to the zsig45 polypeptide, in the presence and absence of the test sample, by a biological or biochemical assay; and determining from the comparison, the presence of the antagonist of zsig45 activity in the test sample. 21. A method of detecting, in a test sample, the presence of an agonist of zsig45 protein activity, comprising: WO99/28467 PCT/US98/25454 118 transfecting a zsig45-responsive cell, with a reporter gene construct that is responsive to a zsig45 stimulated cellular pathway; and adding a test sample; and comparing levels of response in the presence and absence of the test sample, by a biological or biochemical assay; and determining from the comparison, the presence of the agonist of zsig45 activity in the test sample.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98463897A | 1997-12-03 | 1997-12-03 | |
US08984638 | 1997-12-03 | ||
PCT/US1998/025454 WO1999028467A1 (en) | 1997-12-03 | 1998-12-01 | Human thyroid protein zsig45 and dna encoding same |
Publications (1)
Publication Number | Publication Date |
---|---|
AU1540599A true AU1540599A (en) | 1999-06-16 |
Family
ID=25530726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU15405/99A Abandoned AU1540599A (en) | 1997-12-03 | 1998-12-01 | Human thyroid protein zsig45 and dna encoding same |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1042465A1 (en) |
JP (1) | JP2001525172A (en) |
KR (1) | KR20010024690A (en) |
CN (1) | CN1284131A (en) |
AU (1) | AU1540599A (en) |
CA (1) | CA2312048A1 (en) |
IL (1) | IL136477A0 (en) |
NO (1) | NO20002832L (en) |
WO (1) | WO1999028467A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001023567A1 (en) * | 1999-09-28 | 2001-04-05 | Zymogenetics, Inc. | Membrane-bound protein-60 |
JP6161548B2 (en) * | 2014-01-23 | 2017-07-12 | シスメックス株式会社 | Peptide recovery method |
-
1998
- 1998-12-01 KR KR1020007006105A patent/KR20010024690A/en not_active Application Discontinuation
- 1998-12-01 IL IL13647798A patent/IL136477A0/en unknown
- 1998-12-01 CN CN98813254A patent/CN1284131A/en active Pending
- 1998-12-01 EP EP98959647A patent/EP1042465A1/en not_active Withdrawn
- 1998-12-01 JP JP2000523343A patent/JP2001525172A/en active Pending
- 1998-12-01 WO PCT/US1998/025454 patent/WO1999028467A1/en not_active Application Discontinuation
- 1998-12-01 AU AU15405/99A patent/AU1540599A/en not_active Abandoned
- 1998-12-01 CA CA002312048A patent/CA2312048A1/en not_active Abandoned
-
2000
- 2000-06-02 NO NO20002832A patent/NO20002832L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1284131A (en) | 2001-02-14 |
KR20010024690A (en) | 2001-03-26 |
IL136477A0 (en) | 2001-06-14 |
NO20002832L (en) | 2000-07-20 |
CA2312048A1 (en) | 1999-06-10 |
EP1042465A1 (en) | 2000-10-11 |
WO1999028467A1 (en) | 1999-06-10 |
JP2001525172A (en) | 2001-12-11 |
NO20002832D0 (en) | 2000-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1009829B1 (en) | Adipocyte-specific protein homologs | |
US20050240014A1 (en) | Connective tissue growth factor homologs | |
US6388064B1 (en) | Human 2-19 protein homologue, z219a | |
US6500925B1 (en) | Human thyroid protein ZSIG45 | |
CA2320399A1 (en) | A human 2-19 protein homologue, z219c | |
US6902911B1 (en) | Human 2-19 protein homologue z219C | |
AU1540599A (en) | Human thyroid protein zsig45 and dna encoding same | |
US6486304B1 (en) | Antibodies and methods of making antibodies to human thyroid protein zsig45 | |
CA2294702A1 (en) | Mammalian secretory peptide-9 | |
AU2870399A (en) | Connective tissue growth factor homologs | |
US20020182677A1 (en) | Pancreatic and ovarian polypeptide, zsig58 | |
AU4197499A (en) | Immunomodulator polypeptide, zsig57 | |
MXPA00005472A (en) | Human thyroid protein zsig45 and dna encoding same | |
AU5463699A (en) | Pancreatic and ovarian polypeptide, zsig58 | |
ZA200100671B (en) | Pancreatic and ovarian polyptetide ZSIG58. | |
MXPA00012591A (en) | Immunomodulator polypeptide, zsig57 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |